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Abstract
The results reported in this dissertation provide evidence that the cysteine 
protease, cathepsin B, is one of the nonmuscle-specific genes expressed in a regulated 
manner during myogenesis. Unlike muscle-specific enzymes such as creatine 
phosphokinase (CPK), levels of cathepsin B activity are high in dividing, presumptive 
myoblasts. As these cells align in linear arrays in preparation for fusion, levels of 
cathepsin B activity drop dramatically and then increase in a fusion-related manner 
characteristic o f muscle specific enzymes. This current studies appears to be the first to 
demonstrate a “down-up” pattern of cathepsin B activity over the entire differentiation 
process in vitro and to provide both indirect and direct evidence for the role of cathepsin 
B in myogenesis. First, the down-up pattern is observed in both mouse C2C12 and rat 
L6S myoblast cell lines but not in nonfusing L6 myoblast variants or LM fibroblasts. 
Second, during differentiation of C2C12 and L6S myoblasts, cathepsin B is redistributed 
towards the membrane of fusing cells but not during growth of nonfusing variants. Third, 
the cell-membrane permeable cathepsin B selective inhibitor, CA074Me inhibits 
myogenesis in situ. Forth, reduced levels of cathepsin B are associated with alterations in 
the activities of the non-muscle specific biochemical marker, CPK (biochemical 
differentiation) and are associated with a dramatic reduction in the extent of myotube 
formation and size of each myotube (morphological differentiation).
While these observations implicate cathepsin B in myotube formation, there is 
considerable evidence presented in this dissertation to implicate the cysteine protease 
cathepsin L and the aspartyi protease cathepsin D since both demonstrate a similar “up- 
down” pattern of activity during differentiation of L6S but not during growth of non­
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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fusing L6D3 and LM. Moreover, reductions in levels of cathepsin B activity and protein 
in fusing populations of cathepsin B gene-trapped C2C12 myoblasts appears to be 
complimented by increases in levels of cathepsin L-type activity and protein. However, 
cathepsin L-type activity does not appear to compensate for cathepsin B during 
differentiation of cathepsin B gene-trapped myoblasts in vitro.
This study also provides evidence that the down-up pattern of cathepsin B activity 
is regulated at the level of transcription. Levels of cathepsin B activity parallel levels of 
cathepsin B protein and there is an induction in levels of cathepsin B mRNA in fusing 
myoblasts that is not observed in nonfusing myoblasts.
Finally, this research provides evidence that the “down-up” pattern of cathepsin B 
activity and protein expression represents a “house-keeping to differentiation specific 
transition in function, a function necessary for myoblast differentiation. This is also 
supported by ongoing studies demonstrating that cathepsin B promoter activity is induced 
during myoblast differentiation.
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Introduction
1.1 Myogenesis
Myogenesis is a dynamic process that occurs at every stage of development and is 
necessary for muscle function. Descriptively the process of myogenesis is simple and 
consists o f cell proliferation-, recognition- and fusion-related events (Fig. 1). In brief, 
in vivo and in vitro (i.e., in culture), cycling presumptive myoblasts proliferate until 
they withdraw from the cell cycle and become committed to differentiation. 
Committed myoblasts migrate, align, and adhere to each other forming linear arrays of 
noncycling, post-mitotic cells. Myoblasts within these linear arrays then fuse to form 
multinucleated myotubes, the necessary precursors of mature muscle fibres. There is 
no DNA synthesis within myotubes, but their formation (i.e., morphological 
differentiation) is temporally-related to alterations in the expression of numerous 
structural genes (i.e., biochemical differentiation)(Fig. 2). This includes fusion-related 
increases in non-specific proteins such as glycogen synthetase (Luzzati 1972) and 
glycogen phosphorylase (De La Haba et al. 1968) and in muscle-specific proteins such 
as myosin heavy chain (Coleman et al. 1968; Paterson et al. 1972), acetylcholine 
receptors (Dryden 1970), acetylcholinesterase (Fluck et al. 1973) and creatine 
phosphokinase (Shainberg et al. 1971; Morris et al. 1972). A more extensive, albeit 
Incomplete, list of muscle-specific and nonspecific genes expressed in a regulated 
manner during myoblast differentiation is presented in Table 1. Since biochemical and 
morphological differentiation of myoblasts occur at every stage of development,















Schematic Representation of Myogenesis
Myogenesis is the process by which cycling presumptive myoblasts proliferate until they 
withdraw from the cell cycle at Gl. Myogenesis is associated with cell-cell recognition 
events such that committed myoblasts migrate, align and adhere to each other to form 
linear arrays of noncycling post-mitotic cells. Myoblasts within these linear arrays then 
fuse to form multinucleated myotubes (fusion events), the necessary precursors of mature 
muscle fibers.
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Percent Fusion and Creatine Phosphokinase Activity in L6 Rat Myoblasts
L6 rat myoblast homogenates were prepared at each day of growth and differentiation 
and used to determine fusion index (circles) and levels of CPK activity (boxes). CPK 
activity is expressed as units/mg protein where one unit equals that amount of 
micromoles product formed per minute.
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Table 1. Biochemical Gene Expression of Differentiating M urine Myoblasts in Culture 
Products of S tructural Genesfl Pattern(I/D)^ Reference (1st Author, Year)
Glycogen phosphoryiase I de la Baba, 1968
Myosin heavy chain I Coleman, 1968
Acetylcholine receptor I Dryden, 1970
Creatine phosphokinase I Shainberg, 1971
Glycogen synthetase I Luzzati, 1972
Phosphoryiase a I Wahrmann, 1973
Acetylcholinesterase I Fluck, 1973
Myosin light chains I Emerson, 1975
Adenyl cyclase I Dufresne, 1976
Ca^+ -dependent neutral protease I Kaur, 1981
Metalloprotease (MEPr) I Couch, 1983
Cathepsins B, H, and L I Kirschke, 1983
Cysteine Protease Inhibitors I Kirschke, 1983
Fructose di-P aldolase I Turner, 1983
N-cadherin (adhesion protein) I Hatta, 1986
Insulin GF binding protein D McCusker, 1988
P40 polypeptide D Meadus, 1990
N-CAM (adhesion glycoprotein) I Dickson, 1990
Procollagen I Nandan, 1990
Phosphofructokinase I Wills, 1990
Histone H4 D Larson, 1991
Glucose Transporters
GLUT1 D Mitsumoto, 1991
GLUT4 I Mitsumoto, 1991
Adenine Nuclear Translocators
(ANT isofroms) I Stepien, 1992
Laminins-1 and 2 I Schuler, 1995
Citrate synthase, Cytochrome Oxidase I Rochard, 1996
Insulin Growth Factor-! and II D Stewart, 1996
Hepatocyte Growth Factor/Scatter Factor
(HGF/SF), met proto-oncogene (met) D Anastas i, 1997
Syndecan-1 D Larrain, 1997
Cathepsin D I Keller, 1998
Includes both muscle-specific proteins and myogenesis-specific patterns of proteins not specific to
muscle.
I (increase), D (decrease) in protein (iso)forms.
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myogenesis in culture has become a paradigm for the study of regulatory mechanisms 
underlying cytodifferentiation and development.
1.2 Muscle Developm ent: Embry ©genesis
Skeletal myoblasts arise during embryogenesis from precursor mesodermal cells 
called somites (Fig. 3). Somites are transient structures that are important in 
organising the segmental pattern of vertebrate embryos and give rise to the cells that 
form the vertebral ribs, dermis of the dorsal skin, skeletal muscles of the back, and the 
skeletal muscle of the body wall and limbs. The first somites appear at about 8 days in 
the anterior portion of the mouse embryo as a result of segmentation of the paraxial 
mesoderm (unsegmented mesoderm). In chicks, cells of the segmental plate are 
organised into whorls of cells called somitomeres (Meier 1979). Cells of the most 
anterior somitomeres become compacted into a ball of epithelial cells via an increase 
in fibronectin and any of its cells can become any of the somite-derived structures. 
Like the notochord and neural tube, the somite secretes collagen, fibronectin, laminin 
and glycosaminoglycans (GAGs). Through the action of GAGs and other factors 
secreted by the notochord, the cells in the ventral half of the epithelial somite become 
mesenchymal and form the sclerotome, which contains precursor cells for vertebra 
and ribs. The epithelial somitic cells closest to the neural tube (most dorsal) migrate 
ventrally downward and differentiate into a double-layered epithelium called the 
dermamyotome. The dorsal layer of this structure, the dermatome, generates precursor 
cells of the dermis o f the back. Cells located in the medial dermomyotome give rise 
to the back and intercostal muscles [(i.e., epaxial musculature) and cell located in the 
in the lateral dermomyotome give rise to ventral body wall and limb muscles [(i.e.,
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.









Schematic Representation of the Development of the Chick Somite
These illustrations (reproduced from Gilbert, Third Ed., 1991) represent the changing 
structure of the chick somite as cell migrations occurs. The cells of the lateral portion of 
the somite disperse and form the muscles of the limb and body wall. Once the cells of the 
sclerotome and body wall-limb muscle cell precursors have migrated away from the 
somite, the somatic cells closest to the neural tube migrate ventrally down the remaining 
epithelial portion of the somite to form a solid double-layered epithelium called the 
dermomyotome. The dorsal layer of this structure is called the dermatome, and it 
generates the mesenchymal connective tissue of the dorsal skin; the dermis. The inner 
layer of cells is called the myotome and these cells give rise to the vertebral muscles that 
span the vertebra and allow the back to bend.
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faypaxiaJ musculature) (Ordahl and LeDouarin 1992)]. The Inner layer of cells 
between the sclerotome and the deratome is the myotome; this Is the first skeletal 
muscle formed in the embryo and gives rise to the vertebrate muscles that allow the 
back to bend.
Cells o f  the newly formed somite are initially multipotent. They become 
committed to specific fates in response to instructional molecular signals from 
surrounding cell types. For example, the vertebrate homologue of wingless-family of 
secreted glycoproteins involved in cell-cell signalling (i.e., Wnt) produced by the 
dorsal neural tube and surface ectoderm, induces dermamyotome-specific gene 
expression. Another diffusable factor called sonic-hedgehog (Shh) secreted from the 
notochord and ventral floor plate of the neural tube, induces sclerotome-specific gene 
expression and thereby excludes myogenic cells from this region of the somite. In 
addition, the signalling factor, bone morphogenic protein 4 (BMP4), a member of the 
transforming growth factor-(3 superfamily of cytokines is produced by the lateral 
mesoderm and inhibits myogenesis (Katagiri et al. 1997). Lately, a great deal of 
interest has been focused in identifying signalling molecules that divert somitic 
mesodermal cells into the skeletal muscle lineage by induction or repression 
mechanisms.
1.3 Muscle Gene Expression and Fibre Type Specification
In the early embryo, muscle masses do not show fibre type specialization. Rather, 
muscle genes are expressed uniformly in any given muscle at any given time. On the 
other hand, in the fetus, when muscle fibres are in general innervated by numerous
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neurones, fibre type specialization can already be detected in muscle masses in terms 
of muscle gene expression. This partly reflects the presence of secondary fibres 
resulting from the fusion of a population of secondary myoblasts that proliferate 
rapidly, perhaps in response to neuronal or humoral factors (Fig. 4). Secondary (2°) 
fibres can be distinguished from pre-existing primary (1°) fibres on the basis of their 
morphology and their pattern of myosin gene expression (Miller 1991).
Adult skeletal muscle is a highly specialised tissue composed of differentiated 
muscle fibres containing organised arrays of muscle sarcomeres. Fibre types are 
established in the perinatal period and their phenotypes depend directly on the motor 
neurone that contacts the muscle and on other extrinsic factors such as thyroid 
hormone. Different fibre types have different contractile properties reflecting different 
isoform combinations of structural and soluble muscle proteins (Miller 1991), 
products of multigene families.
Throughout skeletal muscle development, expression of different members of 
multigene families begins at different times with subsequent changes in their 
expression occurring independently for each gene (Buckingham 1992). Desmin, titin, 
skeletal and cardiac alpha actin genes are the earliest genes expressed, at least 12 hours 
before the first myosin heavy chain genes. Expression of the fetal heavy chain myosin 
isoform begins soon after and continues throughout embryonic and fetal development. 
At different times within fetal muscle development, most isoforms of the major 
structural genes (e.g., actin, myosin heavy chain, and creatine phosphokinase) are 
expressed in muscle. Some of these continue to be expressed after birth.
Within the rat developing limb muscles, each myoblast population expresses
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Representation of Myogenic Lineage during Higher Vertebrate 
Muscle Development
Embryonic myoblasts in developing axial and appendicular muscles of higher vertebrates 
predominate in the embryo until morphogenesis of the limbs is fully complete. Fetal 
myoblasts predominate in the muscles of the fetus and undergo marked growth through 
new fiber formation (secondary fiber formation), and increase in girth, length and 
nucleation of existing fibers. The transition from embryonic to fetal myoblasts coincides 
with innervation of the limb. Adult myoblasts, important in fiber growth and repair, 
appear in the limb muscles at mid-fetal life and are the predominate myoblast type prior 
to hatching or birth. Within each of these three categories in mammals and birds there can 
be subtypes of myoblasts that in vitro form only specific fiber types.
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a unique pattern of myosin heavy chains such that embryonic myoblasts accumulate 
embryonic and slow isoforms while fetal myoblasts accumulate embryonic, neonatal, 
and adult isoforms. To determine if these two populations of myoblasts could fuse 
with each other and whether the pattern of myosin heavy chain was altered. Pin and 
Merrifield examined fused heterokaryons of these two cell types in culture (Pin and 
Merrifield 1997A). They observed that nuclei contributed by each myoblast cell type 
were surrounded by their own myosin heavy chain isoforms suggesting that myoblast 
specific expression of the isoforms is dictated by cis-acting factors established prior to 
myoblast fusion. Furthermore, Pin (1997) observed that L6 rat myoblasts injected into 
regenerating adult tissues (i.e., in vivo) fused with each other to form homotypic fibres 
as well as with host tissue to form heterotypic fibres. However, fibre analysis indicated 
that myoblast fusion was independent of innervation and that the fibres formed 
expressed only L6 types of myosin heavy chain. These observations suggested that 
fibre formation is regulated in part by intrinsic factors that limit fibre type potential 
(Pin and Merrifield 1997B). In view of such evidence, it is generally agreed that: 1) 
the definitive phenotype of an adult muscle fibre type is the result of events that begin 
in the embryo and are continually modulated and redefined throughout the life of the 
organism, 2) at each stage of development, the formation of myofibrils from 
progenitor myoblasts depends on the expression of the appropriate genes from each 
multigene family pool, and 3) both intrinsic and extrinsic factors contribute to the 
continuum of fibre phenotypes expressed; these factors include the types of myoblasts 
within and between different developmental stages (i.e. embryonic, fetal and adult), 
innervation, workload, hormones and immediate environmental factors (Sutherland et
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11
al. 1991). In other words, muscle fibre formation is highly regulated.
L4 Mechanisms Determining the Myogenic Cell Lineage during Development
From the earliest studies of myoblast differentiation in culture, it was clear that 
myoblasts could be maintained as a proliferating, self-renewing population of cells 
that “remembers” their developmental history (Bischoff and Holtzer 1977; Buckley 
and Konigsberg 1974; Richler and Yaffe 1970). The stability of myogenic phenotypes 
suggests that permanent changes in chromatin structure and gene expression patterns 
are responsible for maintaining cells in a committed determined state. Support for this 
explanation came through studies of immortal CH3-10T1/2 mouse fibroblasts treated 
with the demethylating agent 5-azacytosine in culture (Davis et al. 1987). This agent 
altered the chromatin structure of DNA and transformed fibroblasts into chondrogenic, 
adipogenic, and myogenic cells. On the basis of these studies, it was hypothesized 
(1987) that myoblasts derived from uncommitted fibroblasts continually express 
regulated loci that both activate the expression of lineage specific markers in 
proliferating myoblasts and make these cells competent to express other muscle 
specific genes when induced to differentiate. Using subtraction hybridisation of 
cDNAs representing transcripts expressed in myoblasts but not in 1QT1/2 fibroblasts, 
four vertebrate myogenic regulatory factors (MRFs) were identified: MyoD, 
Myogenin, Myf5 and MyF4. Since they demonstrated the unique ability of inducing 
the myogenic phenotype in fibroblasts, these genes were termed myogenic 
determination genes (Davis et al. 1987). Their discovery was to prove a breakthrough 
towards our understanding of the molecular mechanisms governing skeletal muscle 
gene expression and the types of factors determining them.
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1,4.A. MyoD Family of Musele Specific Transcription Activators
The four myogenic regulatory factors share a basic DNA-binding motif that 
recognises the CANNTG consensus sequence (i.e., E-box) in the promoter or enhancer 
regions of muscle specific genes (Olson 1990; Weintraub et al. 1991) (Fig.5). The 
MRFs also share a helix-loop-helix dimerization domain that allows them to form 
homodimers and heterodimers with other bHLH family members and with products of 
the E2A gene (Weintraub et al. 1991). The MRF genes have different spatial and 
temporal expression patterns in the embryo and in myogenic cell lines. For example, 
MyoD and/or Myf5 levels increase during proliferation of undifferentiated 
presumptive myoblasts in culture, whereas myogenin levels increase later when 
myoblasts become committed to myotube formation. During in vivo development, 
MyoD and myogenin transcripts and proteins co-accumulate in the limb whereas in the 
myotome, myogenin protein is not yet detected. These distinct patterns of expression 
argue for a distinct role for each factor.
“Knockout” of individual MRF genes in mice through embryonic stem cell 
technology provides direct evidence for the biological significance of these factors in 
skeletal muscle development (Table 2). For example, single homozygous MyoD (-/-) 
or Myf5 (-/-) mice demonstrated no skeletal muscle defects (Rudnicki et al. 1993). In 
contrast, double homozygous MyoD/Myf5 knockout mice did not form skeletal 
muscle and showed a complete absence of myogenic stem cells. Together, the single 
and double gene knockout studies suggest that: 1) MyoD and Myf5 can compensate 
for each other, and 2) expression of MyoD or Myf5 is required to generate myoblasts 
during development. Interestingly, homozygous myogenin (-/-) mice produced
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Figure 5
Schematic Representation of a Heterodimer formed by two 
bHLH MRF Proteins
The amphipathic alpha-helices of the HLH motif form a 4-helix bundle resulting in 
juxtaposition of the basic regions to form a bipartite DNA-binding domain (Edmonson 
and Olson 1993). The basic region of each protein recognises a half-size with the dyad 
symmetrical CANNTG E-box DMA sequence found with the promoters and enhancers of 
muscle specific genes.
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Table 2. Sum mary of Muscle Transcription Factor Gene 
Knockout Studies
Gene Knockout Phenotype
Myf-5 no skeletal muscle defects
MyoD no skeletal muscle defects




Myogenin myoblasts do not fuse to form 
myotubes
MRF4 no skeletal muscle defects
D-me£2 somatic, cardiac and visceral 
muscle differentiation defects
(reviewed in Lndolph and Konleczny 1995)
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myoblasts that did not fuse to form myotubes (Nabeshima et al. 1993).
While gene ablation experiments have established the need for MRF genes during 
skeletal muscle development, their precise roles in maintaining the myogenic 
phenotype remains unclear. For example, in the mouse embryo, cells that migrate from 
the dermamyotome to the limb bud are committed to a myogenic fate. However, they 
do not express the myogenic bHLH genes and induce myogenesis until they reach 
their destination. Clues to understanding how these migratory cells maintain their 
commitment to a myogenic fate in the absence of MRF gene expression has come 
from recent studies of the paired box (Pax) gene family.
1.4,8. Pax-3
The paired box gene family encodes transcription factors containing paired 
domains. One member of this family, Pax-3 encodes a 497 amino acid protein 
containing two conserved DNA-binding motifs: an amino terminus domain and a 
paired domain (Grass and Walter 1992; Goulding et al. 1991). During development, 
Pax-3 is expressed in the paraxial mesoderm prior to somitogenesis and in the dorsal 
half of early somites, but is excluded from the myotome. In addition, Pax-3 expression 
is first up-regulated in migratory precursors entering the limb buds from the 
dermamyotome then down-regulated as these cells begin differentiating (Jostes et al.
1991).
The first indication for a role for Pax-3 in skeletal muscle development came from 
the phenotype of the splotch mouse mutant, which lacks a functional Pax-3 gene and is 
devoid of limb muscle (Bober et al. 1994). Using transplantation techniques, it was 
demonstrated that when the lateral halves of somites (limb precursors) derived from
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splotch mice were transplanted into the limb buds of chick embryos, the mutant mouse 
myoblasts recovered their ability to differentiate. The target for Pax-3 was 
subsequently correlated to the absence of c-met gene expression for a migratory 
growth factor. In the absence of c-met induction by Pax-3, the lack of migratory 
growth factor signalling would effectively shut down migration of precursor limb cells 
to the limb buds (Yang et al. 1996).
Recently, Buckingham’s group has combined Pax-3 and Myf-5 mutations by 
inter-crossing mice carrying each mutation (Tajbakhsh et al. 1997). Progeny mice 
lacking both genes neither expressed MyoD in the trunk nor developed skeletal muscle 
in this region. These data supported an essential role for Pax-3 as a regulator of MyoD 
expression. Since Pax-3 and MyoD have been shown to express mutually exclusive 
patterns in the somite and the limb bud, it was suggested that this role would be 
associated in the activation rather than maintenance of MyoD expression. Several 
lines of evidence support this activation role. First, forced expression of Pax-3 induces 
MRF gene expression in cultured paraxial mesoderm and dermal fibroblasts (Marato et 
al. 1997). Second, forced expression of Pax-3 in 10T1/2 fibroblasts blocks MyoD- 
induced skeletal muscle gene expression (Epstein et al. 1995). Third, forced 
expression of Pax-3 in the C2C12, mouse myoblast cell line blocks differentiation 
(Epstein et al. 1993). Together these observations suggested that unique combinations 
of positive and negative regulatory factors present in different cell types influence the 
myogenic functions of Pax-3. A model of regulatory interactions involving Pax-3 
during skeletal muscle development has been suggested (Fig. 6). In this model, the 
neural tube and notochord factors Wnt and Shh induce Myf-5 and Pax-3 expression in
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A Model of Regulatory Interactions Involving Pax-3 during 
Skeletal Muscle Development
Shli and Wnts produced by the neural tube and notochord, respectively, cooperate to 
induce Myf-5 and Pax-3 expression in the somites. Myf-5 regulates the early expression 
of MyoD, whereas Pax-3 regulates the late expression of MyoD. Pax-3 also regulates c- 
met expression required for migration of muscle precursor cells to the limb bud. Surface 
ectoderm also induces myf-5 and MyoD expression. (Reproduced from Rawls and Olson 
1997)
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the somites. Myf-5 and Pax-3 then play a role in regulating the early and late 
expression of MyoD, respectively. According to this model, Pax-3 would also play a 
role in regulating c-met expression necessary for migration of muscle precursor cells 
to the limbs. This model provides a general framework for further analyses to define 
the precise role of Pax-3 in muscle development.
I.4.C. Twist
Twist was originally identified in Drosophila as a gene necessary for embryonic 
gastrulation and formation of mesoderm (Simpson 1983) and is now recognised as a 
bHLH protein that is expressed in mesoderm. During vertebrate embryonic 
development, Twist is initially expressed throughout the somitic mesoderm. As the 
somite develops, Twist is excluded from the forming myotome but continues to be 
expressed in other mesodermal structures such as the dermamyotome, sclerotome and 
lateral plate mesoderm (Wolf et al. 1991; Fuchtbauer 1995). These observations 
supported two inter-related hypotheses: 1) that Twist functions to negatively regulate 
myogenic factors such as the basic helix-ioop-helix MRFs, and 2) that mutually 
exclusive expression of Twist and MRFs partitions the somitic mesoderm into 
alternative cell fates. These hypotheses have been supported by observations 
demonstrating that Twist inhibits muscle-specific gene activation during early embryo- 
genesis by the formation of active inhibitory complexes which bind to E-box elements 
and consequently inhibit the binding of bHLH MRF to DNA (Hebrok et al. 1997; 
Spicer et al. 1996). Regardless of the detail, the current consensus is that Twist 
inhibits the MyoD family of muscle regulatory factors during early embryogenesis and 
thus regulates myotome formation spatially and temporally.
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I.4.D. Inhib itor of MyoD Family (I-mf)
During experiments to isolate embryonic proteins that interact with MyoD using 
the yeast two-hybrid system, Chen et al. (1996) isolated a novel myogenic repressor, I- 
mf, which was highly expressed in the sclerotome where MyoD expression is 
excluded. These researchers demonstrated that I-mf associates with MRFs in the 
cytoplasm thereby masking their nuclear localisation signals by preventing binding of 
MRFs to target DNA sequences (Chen et al. 1996). These and similar observations 
support the hypothesis that I-mf is involved in maintaining the identity of the 
sclerotome by restricting the expression and function of myogenic factors.
1.5 Mechanisms Determining Gene Expression During Myogenesis
1.5.A. Helix-Loop-Helix (HLH) Proteins
While the MRF factors act in combination with up-stream regulatory factors such 
as Wnt, Shh, Pax-3, Twist and I-mf to initiate cell determination and to maintain 
myogenic lineage specification, they are also the only factors thus far identified that 
function to regulate the expression of muscle-specific genes during myoblast 
differentiation. The unique ability of MRFs to generate the myogenic phenotype is 
particularly interesting given that they are part of a much larger family of bHLH 
factors. Analyses of cloned MRFs demonstrate that this ability is highly conserved; 
for example, myogenic bHLHs from sea urchin and C. elgans efficiently activate 
myogenesis in 1QT1/2 mouse fibroblasts (VeuntI et al. 1991; Chen et al. 1992).
The basic HLH motif defines a superfamily of proteins that regulate cell-type specific 
transcription and includes the four MRF factors that regulate myogenesis, the 
Drosophila achute-scute complex that regulates neurogenesis, and Twist which
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regulates mesoderm formation. Members of the Myc family of oncogene products, 
and their dimerization partner Max, also contain conserved bHLH motifs. Basic helix- 
loop-helix MRF proteins heterodimerize with E-class proteins forming complexes that 
activate the expression of muscle-specific genes by binding to E-box elements (i.e., 
CANNTG consensus sequences) in their promoters and enhancers. Helix-Joop-helix 
proteins that lack functional basic domains can also dimerize with E-proteins. 
However, these complexes which prevent the expression of muscle-specific genes are 
termed inhibitors of differentiation (Id). Inhibition is predominant in cycling, 
presumptive myoblasts where high levels of Id act to negatively regulate MRF 
function by competing with MRF for E-protein partners. Inhibition of myogenesis has 
been correlated to the overexpression of Id in myoblasts exposed to some sera (Jen et 
al. 1992). This observation suggested that overexpression, and consequently the 
inhibition of myogenesis, is signalled by growth factors in the serum. However, the 
same authors also reported that cells maintained in medium containing high 
concentrations of FGF-2 or TGF-B1 did not over-express Id even though myogenesis 
was inhibited (Jen et al. 1992). This latter observation suggested that additional 
pathways operating at other levels including the post-translational level, could act to 
negatively control myogenesis (Fig. 7). Evidence supports this possibility. Cyclic 
AMP and protein kinase C have been shown to phosphorylate the conserved threonine 
residues located within the basic domains of MRFs thereby inhibiting these factors 
from binding to regulatory regions of muscle-specific genes (Li et al. 1992A). Binding 
of the immediate early gene products, Fos and Jun, to MRFs has also been shown to 
inhibit the function of MRFs in myogenesis (Edmonson et al. 1993). These studies













I 1 |c A n InItIg • 1 ji i J i ■ i
Figure 7
Positive and Negative Regulation of MRFs via HLH Protein Dimerization
This is a schematic representation of bHLH and HLH protein interactions that act to 
regulate transcription. In A, MRF proteins heterodimerize with E-class proteins (E-12 or 
E47) to positively regulate skeletal muscle specific gene expression, whereas in B, high 
levels of Id HLH act to negatively regulate MRF function by forming heterodimers with 
E-proteins thereby competing with MRFs for E-protein partners.
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demonstrate that transcriptional repression by c-Jun can be mediated by direct 
interactions between the leucine zipper of c-Jun and the bHLH region of MyoD.
Skerjanc el al. (1996) have reported another bHLH factor, termed MITF, that 
forms active heterodimers with MRFs. MITF belongs to the ubiquitously expressed 
IF2-2 family of bHLH proteins. Skeijanc et al. (1996) have isolated cDNAs derived 
from 2 alternatively spliced forms of mouse ITF-2 termed MITF-2A and -2B. 
Structure and function analysis of cDNAs derived from 2 alternatively spliced forms 
of mouse ITF-2, MITF-2A and MITF-2B, demonstrated that excess MITF-2A inhibits 
the inhibition of MyoD by Id, while excess MITF-2B inhibits MyoD activity by 
forming inactive heterodimers with it. Thus, differentially spliced transcripts of mouse 
ITF-2 encode two distinct proteins that dimerize with MyoD and either activate (i.e., 
MITF-2A) or repress (i.e., MITF-2B) the expression of muscle-specific genes.
Cell cycle regulators that play key roles in regulating the transition from 
proliferation to differentiation in most cells are also essential in controlling myogenic 
events. For example, it has been reported that hypophosphorylated retinoblastoma 
(RB) is required for myoblasts to withdraw from the cell cycle and to fuse into 
myotubes (Gu et ah 1993). Unphosphorylated RB interacts directly with MyoD in 
vivo via the pocket and bHLH domains, respectively. Inactivation of retinoblastoma by 
phosphorylation abolishes MyoD interactions leading to inhibition of myogenesis. 
Phosphorylation of RB by cyclin D1 also prevents MRF activation and maintains cells 
in the uncommitted, cycling state, while ectopic expression of p21clpl (inhibitor of 
cyclin/cdk complexes) enhances the ability of MyoD to generate a skeletal muscle 
phenotype, even in the presence of high serum concentrations (Halevy et al. 1995).
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In general, sequence specific transcription factors are comprised of two critical 
regions, a DNA binding region that directs the factor to the vicinity of the promoter 
and a transcriptional activation region that directly or indirectly interacts with other 
factors. In the case of muscle-specific MRF transcription factors, these other factors 
include DNA binding proteins, transcriptional activators, accessory proteins, co­
activators and adaptors. It is becoming increasingly apparent that muscle-specific 
gene transcription will be defined in part by the formation of specific combinations of 
multi-component complexes that assemble on the promoters of muscle specific genes. 
Two non-specific classes of factors, MLP and MEF2, appear to be particularly 
important in the expression of muscle-specific genes.
I.5.B. Muscle LIM Protein (MLP)
Several lines of evidence suggest that co-factors play an important role in muscle 
gene expression. These co-factors are most likely co-regulatory proteins involved in 
muscle-specific transcription mechanisms essential for muscle-specific gene 
expression. One such positive co-regulator was isolated from a subtracted cDNA 
library enriched in genes induced in skeletal muscle by denervation (Arber et al. 
1994). This protein was subsequently termed Muscle LIM Protein (MLP) owing to the 
presence of two LIM finger structures in its sequence, its expression pattern and its 
role in myogenic differentiation.
The LIM domain is a cysteine-rich motif that was initially identified in three 
developmentally important transcription factors referred to as Lin-11, Isl-1, and Mec3 
(Sanchez-Garcia and Rabbits 1994). This domain defines a specific zinc binding 
structure which co-ordinates two atoms of zinc in a tetrahedral fashion via the
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conserved cystidine and histidine residues in the LIM consensus sequence. The MLP 
gene is expressed predominantly in skeletal and cardiac muscles and is dramatically 
upregulated during myoblast differentiation. While the mechanisms by which MLP 
induces myogenesis remain largely unknown, several studies have demonstrated that 
LIM proteins can associate with bHLH factors to synergistically activate muscle gene 
expression (German et al. 1992; Wadman et al. 1994). The high levels of MRF and 
MLP proteins during myoblast differentiation are consistent with this possibility.
L5.C. Myocyte Enhancer Factor 2 (MEF2)
Recent studies have provided evidence for a complex regulatory network between 
members o f the muscle bHLH and MEF-2 family of transcription activators. The 
MEF2 family belongs to the MADS superfamily (MCM1, agamous, deficiens. and 
serum response factor) of DNA binding proteins. Four distinct genes, MEF2A. 
MEF2B, MEF2C, and MEF2D, make up the MEF2 family of muscle transcription 
factors. These factors bind to a conserved A/T-rich DNA sequence (i.e., MEF2 site) in 
the promoters and enhancers of many muscle-specific genes (Gossett et al. 1989; 
Martin et al. 1994). Members of the MADS superfamily share a 56 amino-acid motif 
(i.e., MADS box) that is responsible for DNA binding and protein dimerization. MEF2 
factors also contain a unique, conserved 29-amino acid sequence (i.e., MEF2 domain) 
involved in DNA binding. It has been demonstrated that MEF2 proteins form 
complexes with other MEF2 family members. Once formed, these complexes can 
activate the transcription of numerous muscle specific genes including M-creatine 
kinase, myosin heavy chain, desmin and certain MRFs (Martin et al. 1994; Chambers 
et ah 1992; Lilly et al. 1994). Unlike the MRFs, MEF2 genes are expressed in a broad
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range of cell types including neural crest cells, cardiac muscle, skeletal muscle and 
visceral muscle cells (Edmonson et al. 1994). However, there is convincing evidence 
that post-transcriptional modifications of MEF2 proteins expressed during muscle 
development effectively restrict the expression of MEF2 transcripts to skeletal and 
cardiac muscle (Martin et al. 1994). The functional significance of this restricted 
expression is the focus of considerable research interest.
There is increasing evidence suggesting that MEF2 and myogenic bHLH proteins 
act within a regulatory network that establishes the differentiated phenotype of skeletal 
muscle. For example, forced expression of myogenin or MyoD in non-muscle cells 
was shown to induce MEF2 DNA-binding activity, suggesting that MEF2 lies within a 
regulatory cascade downstream of the myogenic bHLH protein (Chambers et al. 
1992). However, MEF2-DNA binding sites are usually positioned next to MRF 
binding sites in the promoters and enhancers of muscle-specific genes, including 
MRFs. Moreover, a MEF2 site within the myogenin promoter has been shown to be 
essential for myogenin transcription in cultured muscle cells and mouse embryos 
(Cheng et al. 1993; Yee and Rigby 1993). Together, these studies suggest that both 
MEF2 and myogenin bHLH proteins are involved in reciprocal regulatory circuits that 
amplify and maintain the expression of both families of regulators. Additional studies 
regarding the co-operativity of these two regulators demonstrated that the MADS 
domain of MEF2 proteins interacts with the basic domain and helix 1 o f MRF proteins 
to synergistically activate reporter genes containing MEF2 and E-box elements 
(Kaushal et al. 1994). Analysis of deletion mutants by reporter gene transfections has 
further demonstrated that the synergistic action of MEF2 and MRF regulators requires
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
26
that only one of the two factors bind to DNA. and that only one of the two factors 
possess a transactivation domain (Molkentin and Olson 1996). The factor-mediated 
activation o f gene expression through the DNA binding site of a second factor 
represents a novel mechanism for the regulation of muscle-specific gene expression. It 
is worth noting that this mechanism also provides an explanation for the MRF-induced 
activation o f muscle-specific genes lacking E-box elements in their regulatory regions.
1.6 Interactions Affecting the Myogenic Pathway
While the MyoD family of bHLH myogenic regulatory proteins act to determine 
and maintain skeletal muscle cell lineage, it has become increasingly clear that they act 
at all stages of muscle development with other factors as part of a cascade of events 
that regulate the physiological events associated with myoblast differentiation and the 
transcription of non-specific and muscle-specific genes temporally related to the fusion 
process (Fig. 8). Because regulators within the cascade act in combinations, small 
changes in the relative concentration of a single component can have large effects on 
the expression of the cell’s differentiation state, for example, by shifting a critical 
balance, reaching a threshold, and setting off another cascade of events. While the 
concentrations of regulators change in response to internal molecular cues, they also 
occur as a result of extracellular cues, for example, the interaction of myogenic cells 
with extracellular matrix molecules and with other cells.
1.6.A, Cell-Extracellular Matrix (ECM) Interactions
In vitro studies in myoblast culture systems suggest that the stable expression of 
the myogenic phenotype is affected by interactions between the cell and its 
extracellular matrix (Matrisian and Hogan 1990; Adams and Watt 1993). Alterations
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Figure 8
Summary of a Myogenic Regulatory Cascade Model
Pax-3 as well as the MRF genes MyoD and Myf-5 act to determine and maintain skeletal muscle cell lineage. Myoblasts remain in a 
proliferative, undifferentiated state when maintained in the presence of serum growth factors due to the cell cycle regulated gene 
products cyclin D1 and retinoblastoma (Rb). In low serum, Rb becomes hypophosphorylated with the aid of p21clpl, inducing cell 
cycle arrest and the transcriptional activation of the myogenin and MEF2 genes. Early differentiation events are signified by the fusion 
of myoblasts into multi nucleated myotubes and the expression of muscle-specific gene products; such as myosin, actin and creatine 
phosphokinase. Later differentiation events involve the expression of the MRF4 and MLP genes and innervation of primary muscle 
fibers.
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in specific extracellular matrix components have been shown to affect differentiation 
in either a positive or negative way. For example, von der Mark and Ocalan 
demonstrated that migration of myoblasts and myotube formation were enhanced if 
myoblasts were cultured in tissue culture dishes coated with collagen or iaminin; in 
contrast, these events were inhibited by the addition of fibronectin (von der Mark and 
Ocalan 1990).
There seems to be at least three mechanisms by which the extracellular matrix can 
regulate cell behaviour during differentiation. One is through the synthesis and 
composition of the extracellular matrix. For example, different variant forms of agrin 
have different abilities to mediate acetylcholine receptor clustering during myoblast 
differentiation (Ferns et al. 1992). Procollagen synthesis/processing in skeletal 
myoblasts is also important in early myogenesis. Treatment of cultured myoblasts 
before alignment with ethyl-3,4-dihydroxybenzoate, a specific inhibitor of procollagen 
synthesis, decreases the amount of glycoprotein (GP46) present in the endoplasmic 
reticulum in non-fused myoblasts and in the membrane of myotubes (Nandan et al. 
1990). Nandan (1990) and others isolated and identified GP46 as a 45 kDa heat-shock 
glycoprotein and found that it is expressed in a differentially regulated manner and is 
critical to procollagen synthesis (Nandan et al. 1990; Pak et al. 1996).
The second mechanism is through synergistic interactions between growth factors 
and matrix molecules. For example, binding of basic fibroblastic growth factor 
(bFGF) to cell surface heparin sulphate proteoglycans is necessary for binding to high 
affinity receptor, and both these interactions are necessary to inhibit myoblast terminal 
differentiation by bFGF (Rapraeger et al. 1991).
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The third mechanism is through the cel! surface receptors that mediate adhesion 
to extracellular matrix components. For example, the surface expression of B1 
integrins changes as myoblasts fuse to form myotubes (Damsky et al. 1985), and 
treating myoblasts with antibody specific to matrix receptors inhibits fusion (Menko 
and Boettiger 1987).
1.6.B Cell-Cell Interactions
The fusion of post-mitotic myoblasts to form multinucleated myotubes is 
preceded by cell alignment, cell recognition and cell adhesion events (Nameroff and 
Manor 1976; Dufresne et al. 1976; Knudsen and Horwitz 1977; Wakelam 1985). 
These events are accompanied by the formation of cytoplasmic bridges and gap 
junctions between myoblasts, alterations in cell shape, and alterations in the molecular 
mass and distribution of membrane proteins (Kalderon 1980; Balogh et al. 1993). 
Alterations in membrane composition include the loss of fibronectin, a large 
glycoprotein from the surface of fusing myoblasts (Pauw and David 1979; Hynes and 
Yamada 1982), the redistribution of the large external transformation-sensitive (LETS) 
protein over the cell surface of fusing myoblasts (Chen 1977) and the reorganisation of 
glycosylated proteins (Gilfix and Sanwal 1980; Olden et al. 1981). More recent 
evidence suggests that two types of cell surface glycoproteins, the cell adhesion 
molecules (CAM) N-CAM and the C-cadherins, co-accumulate at the area of contact 
between aligned myoblasts and mediate myoblast-myoblast adhesion (Anderson 
1990). Although CAM and cadherins co-accumulate, they appear to act 
independently; the former in a calcium independent adhesion mechanism, the latter in 
a calcium dependent adhesion mechanism (Mege et al. 1992). Fusion of the lipid
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bilavers of adherent myoblasts is accompanied by enlargement of cytoplasmic bridges 
and by the partial disappearance of the plasma membrane between the fusing 
myoblasts (Lipton and Konigsberg 1972; Hynes et al. 1976). Significantly, the 
disappearance of the plasma membrane during myotube formation has been associated 
with a redistribution of vesicles (Kalderon and Gilula 1975; Brustis et al. 1994).
L6.C The Effect of Cell-Environmeut Interactions on Gene Expression 
It is generally agreed that at each stage of differentiation, signals from the 
extracellular environment are sensed by myoblasts through different signalling 
mechanisms. It is further agreed that these signals are transmitted to the nucleus 
where, in co-ordination with internal signals, expression of the myogenic phenotype is 
regulated. Studies concerning the formation of gap junctions during myogenesis 
provides a recent example of this type of communication.
Balogh et al. (1993) used antibodies specific to connexin 43 to examine the 
relationship between gap junction formation and myoblast differentiation. They 
observed that levels of connexin 43 increased as myoblasts fused to form myotubes. 
Since connexin 43 is a gap junction protein, they concluded that the formation of gap 
junctions was temporally related to the fusion process. In a later study, Proulx et al. 
(1997) demonstrated that myogenin and MRF4 were not expressed in myoblasts 
exposed to gap junction inhibitors. The results of these studies suggest that 
communication via gap junctions plays an important role in the signalling events that 
trigger muscle-specific MRF gene expression (Proulx et al. 1997).
Finally, there is convincing evidence that changes in cell shape due to interactions 
among extracellular matrix components (e.g., integrin with the muscle-specific focal
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contact protein dystrophin) or with neighbouring cells lead to reorganisation of the 
cytoskeleton. This reorganisation also appears to play a role in signal transduction 
during myogenesis (Weitzer et ah 1995).
1.7 Evidence fo r the Role of Proteases during Myoblast Fusion
The catabolic restructuring implicit in the structural alterations that precede 
myotube formation, the alterations in cell-ECM and cell-cell interactions, and in the 
modulation of regulatory factors suggest a role for cellular proteases during 
myogenesis. Studies conducted over the last thirty years support this suggestion.
By 1980, changes in proteolysis in muscle tissues were well documented but 
overall levels in skeletal muscle were extremely low (Bird et ah 1968; Bird 1975). 
These levels were thought to reflect the low average turnover of muscle proteins in 
normal adult muscle tissue (Bohley and Seglen 1992). This rather ordinary 
interpretation dismissed the biological significance of proteases and negatively 
affected research in the area. In retrospect this interpretation reflected a limitation of 
the experimental system. The inherent structural complexity of whole tissue
homogenates would have made it difficult to assign a specific role for a protease 
within a particular cell type. Moreover, the fact that the majority of skeletal muscle 
cells in whole muscle tissue are incorporated within terminally differentiated muscle 
fibres, would have made it difficult to examine myogenesis in progress. The 
establishment of homogenous populations of mortal and immortal L6 and L8 rat 
myoblast cell lines that retained the capacity to differentiate in vitro (Yaffe 1968, 
1971) overcame these limitations and signalled a renewed effort to identify proteases 
associated with skeletal muscle differentiation.
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1.7.A. The Involvement of Nonlysosomal Proteases in Myogenesis 
Studies using primary myoblasts and the immortal L6rat myoblast cell line 
provided support for the involvement of nonlysosomal proteases. For example, Kaur 
and Sanwal (1981) demonstrated a fusion-related increase in levels of calcium 
activated neutral protease (CANP), a nonlysosomal protease previously implicated in 
the turnover of muscle fibre components (Reddy et al. 1975; Dayton et al. 1976). 
Using immunofluorescence and immunoblot analyses, in later studies, Schollmeyer 
(1986) demonstrated an association of calpain II, one of the two types of CANP, I & 
II, with the plasma membrane of fusion-capable L8 and L6 rat myoblasts but not with 
the membranes of nonfusing variants. The necessary involvement of calpains in both 
intracellular and extracellular membrane fusion events was suggested by studies in 
C2C12, an immortal mouse myoblast cell line. Addition of calpain selective inhibitors 
to C2C12 myoblasts in culture prevented myotube formation (Hayashi et al. 1996).
Additional evidence implicating CANPs in myoblast differentiation came from 
more recent studies using mortal rat myoblasts established from embryonic muscle 
tissue. For example, Brustis et al. (1994) demonstrated that the addition of m-calpain 
to mortal rat myoblasts in culture induced precocious fusion and that cells incubated 
with m-calpain specific antibodies had detectable m-calpain on their cell surface 
membrane. A functional role for this association was provided by Dourdin et al. 
(1997) who demonstrated that fusion of mortal rat myoblasts required fibronectin 
degradation by exteriorized m-calpain activity.
Studies regarding mechanisms regulating calpain-mediated fusion of L8 rat 
myoblasts suggest that the level of calpain is regulated in part by levels of its
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endogenous inhibitor, calpastatin (Barnoy et al. 1997). Levels of this inhibitor were 
shown to drop 10-fold at the onset of C2C12 myotube formation.
In addition to calpains, there is evidence for the involvement of nonlysosomal 
metalloproteases in myoblast-myobiast fusion. For example, Couch and Strittmatter 
(1983) demonstrated that the addition of irreversible metalloendoprotease inhibitors 
and synthetic dipeptide substrates to immortal rat myoblasts prevented their fusion. 
The same authors used a flourogenic metalloprotease selective substrate to localise the 
enzyme to the membrane of fusing myoblasts (Couch and Strittmatter 1983). The 
association of metalloendoproteases with the membrane of fusing myoblasts was 
subsequently confirmed by studies conducted by Kayalar and Wong (1989) in the L6 
rat myoblast system. They demonstrated that metalloendoprotease inhibitors inhibited 
greater than 90% of a 11 OkDa insulin degrading enzyme activity residing in the 
myoblast cytoplasm. Moreover, they suggested that the insulin degrading enzyme was 
a metalloprotease necessary for the initiation of morphological and biochemical 
differentiation of L6 rat myoblasts. There is now evidence that metalloproteases are 
also secreted from differentiating L6 rat myoblasts (Matrisian 1992; Guerin and 
Holland 1995).
I.7.B. The Involvement of Lysosomal Proteases in Myogenesis
Whole tissue studies provided the first evidence for the involvement of lysosomal 
proteases in skeletal muscle cell differentiation (Canonicio and Bird 1970; Stauber and 
Bird 1974). Using cytochemical techniques, two populations of lysosomes isolated 
from tissue homogenates by centrifugation were shown to contain a complement of 
proteolytic enzymes that included members of the cysteine and aspartyl classes of
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endopep tidases (Bird et al. 1978). A role for these lysosomal proteases was suggested 
by the observations that secondary lysosomes of skeletal muscle tissue contained 
fragments o f myofilaments (Libelius et al. 1979), and immunoprecipitates of actin and 
myosin fragments were discovered in skeletal muscle lysosomes treated with antibody 
to actinomyosin fragments (Gerard and Schneider 1979). The concomitant finding 
that the lysosomal aspartyl protease, cathepsin D, and the lysosomal cysteine 
proteases, cathepsins B, H and L, degraded native and denatured actin and myosin 
(Schwartz and Bird 1977; Bird et al. 1980), provided convincing support for the 
involvement of lysosomal proteases in skeletal muscle cell differentiation.
Studies using L6 rat myoblasts were the first to demonstrate that a fully functional 
lysosomal apparatus was present in cultured murine muscle cells, and that increases in 
specific activities of lysosomal catabolic enzymes paralleled myoblast-myotube 
differentiation. For example, Bird and colleagues found that when azocasein was used 
as a substrate, levels of cysteine protease cathepsins B, H and L activities were at least 
two orders of magnitude greater in cultured L6 cells as compared to skeletal muscle 
tissue homogenates (Bird et al. 1981). Moreover, levels of cysteine protease activities 
increased 6 to 7-fold in post-fusion cells. By using more sensitive flourometric 
substrates (Barrett and Kirschke 1981), the fusion-related increase in cysteine protease 
activities was shown to reflect a 5-fold increase in cathepsin L-type activity, a 2-fold 
increase in cathepsin B activity, and a 7-fold increase in cathepsin H activity (Kirschke 
et al. 1983). Our studies in the early 1990s provided evidence that the cysteine 
protease, cathepsin B, played a more specific role in myoblast differentiation (Jane and 
Duffesne 1994).
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1.8 The Involvement of cathepsin B in Myogenesis
Cathepsin B (EC 3.4.33.1) is a member of the cysteine protease class of proteases. 
It acts as an endopeptidase by cleaving internal peptide bonds favouring a large 
hydrophobic side-chain in the substrate and two amino acid residues TV-terminal to the 
scissile bond. Cathepsin B also acts as a peptidyldipeptidase, an exopeptidase that 
removes dipeptides from the C-terminus of proteins and peptides (Aronson and Barrett 
1978). The main function of cathepsin B is to degrade proteins that have entered the 
lysosomal system from outside the cell by means of endocytosis or phagocytosis, or 
from other compartments within the cell by means of autophagy (Bohley and Seglen
1992).
The ubiquitous distribution of cathepsin B in mammalian cells suggests that it 
plays an important but non-specific role in all cells (i.e., a “housekeeping” function). 
Comparisons of cathepsin B transcript and activity levels in a wide spectrum of murine 
and human tissues provided the first evidence for a more specific role for cathepsin B 
in some tissues. For example, levels of rat cathepsin B transcripts were found to vary 
over 10-fold in various tissues; mRNA levels were greatest in kidney then 
progressively decreased in spleen, lung, brain, heart, liver, and thymus (San Segundo 
et al. 1986; Qian et al. 1989). A similar comparative study of human cathepsin B 
activity in various adult tissues demonstrated high levels of activity in liver, thyroid, 
kidney and spleen, intermediate levels in heart, colon, adrenal and lung, and low levels 
in prostate, nerve, pancreas, brain and skeletal muscle (Shuja et al. 1991).
The initial screens for cathepsin B expression were ultimately important in 
identifying tissues in which cathepsin B plays a more specialised role including: 1) the
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generation o f thyroid hormones by proteolytic processing of their precursor, 
thyroglobulin in the thymus, 2) the cleavage of the invariant (li) chain of the class II 
major histocompatibility complex in cells associated with the immune response, and
3) the activator of enzymes directly involved in bone breakdown (reviewed in Mart 
and Buttle 1997).
While tissues with the greatest levels of cathepsin B were the obvious first choice 
to identify specific roles for cathepsin B, tissues with lower levels could not be 
excluded from the search. As previously noted, tissues are by nature heterogeneous. 
Advances in cell culture systems and in cell and molecular techniques permitted a 
more careful examination of levels of specific proteases within specific cells of a 
tissue.
I.8.A. Cell Culture Studies of Cathepsin B in Myogenesis
Since their establishment, the immortal L6 rat myoblast cell line (Yaffe et al. 
1968) and the immortal C2C12 mouse myoblast cell line (Yaffe and Saxel 1977) have 
been the models of choice to study cytodifferentiation in vitro. They have logically 
become the systems of choice to study the role of cathepsin B in myogenesis.
In one of the first studies published in the area, Bird et al. (1981) demonstrated 
that extracts of cultured L6 rat myoblasts contained levels of cysteine proteases that 
were at least two orders of magnitude greater than in muscle tissue extracts. In the case 
of cathepsin B, the activity was 133 times greater in L6 rat myoblasts than in whole 
muscle tissue extracts. Bird’s group reported that fused populations o f L6 myoblasts 
had 6-7 fold greater cathepsin B specific activity than prefusion myoblasts. 
Differentiation-related differences in levels of cathepsin B activity were not observed
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in nonfusing subclone of L6: levels in this subcione were 12-fold higher than those in 
prefusion L6 myoblasts. Using the fluorescent lysosomal marker, acridine orange, to 
localise lysosomes. Bird et al. also observed a more ubiquitous distribution of 
lysosomes in fusing myoblasts compared to a perinuclear distribution in prefusion 
myoblasts. Since these early studies, there has been considerable research effort to 
determine the mechanisms underlying the alterations in cathepsin B activity during 
myogenesis, and the biological significance of these alterations in myogenesis.
L8.B. Mechanisms Regulating the Expression of Cathepsin B 
Alterations in cathepsin B activity can occur by a number of mechanisms (Fig. 9). 
These include alterations in transcription, in translation, in post-translational 
processing and cell targeting, and in levels of endogenous inhibitors. In 1983 Kirschke 
et al. reported that differences in levels of cathepsin B activity between prefusion and 
fused L6 populations were not accompanied by significant alterations in levels of 
endogenous cathepsin B inhibitor activity. These observations were confirmed by our 
more detailed 1994 studies in L6 rat myoblasts (Jane and Dufresne 1994). Ebisui et al.
(1995) subsequently reported that levels of B-cystatin mRNA increased by 60% as 
C2C12 mouse myoblasts fused to form myotubes. Despite this increase, cathepsin B 
activity was 2.5-fold greater in fused populations. The results of these 
inhibitor/activity studies support the involvement of other mechanisms to explain 
alterations in levels of cathepsin B activity during myogenesis.
Evidence for transcriptional mechanisms was provided by the early studies of 
Collela et al. (1986). They reported that fusion-related increases in levels o f cathepsin 
B activity were accompanied by increases in cathepsin B mRNA. These results were
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Levels of Regulation of Cathepsin B Activity
The cathepsin B gene is transcribed as a heterologous nuclear RNA (hnRNA), processed 
to mRNA and transported to the cytosol. Due to the presence of a signal peptide, 
procathepsin B is synthesised on the polysomes of the rough endoplasmic reticulum 
(RER). Maturation of cathepsin B is coupled with intracellular trafficking and includes 
co- and post- transcriptional glycosylation and proteolytic processing events. Fully 
processed cathepsin B can be found in the lysosome, associated with the plasma 
membrane, or secreted. Procathepsin B can be secreted, perhaps through the default 
pathway of vesicular proteins. Inhibition of cathepsin B is mediated by low Mr mass 
inhibitors called cystatins. (Reproduced from Berquin and Sloane 1996)
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confirmed in a more recent study by Ebisui et al. (1995) using C2C12 mouse 
myoblasts. In this myoblast system, fusion-related increases in levels of cathepsin B 
activity were associated with increases in both cathepsin B mRNA and protein. There 
is also evidence for post-transcriptional mechanisms. For example, Bechet et al. 
(1991) reported that in mortal, bovine myoblasts, fusion-related increases in cathepsin 
B activity were not accompanied by increases in levels of cathepsin B protein or 
mRNA. On the basis of these results, they suggest that alterations in cathepsin B 
activity reflect alterations in cathepsin isozyme forms.
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1.9 Experim ental Hypothesis
Taken together, the studies concerning the expression of cathepsin B during 
myogenesis suggest that myoblast fusion is associated with an increase in cathepsin B 
activity that is most likely regulated by transcriptional and post-transcriptional 
mechanisms. It should be pointed out however, that none of these studies provide 
direct evidence of a more specific role for cathepsin B during myogenesis. With this 
in mind, I have hypothesized that the regulated expression of cathepsin B plays a 
necessary role in the differentiation of mononucleated myoblasts to form 
multinucleated myotubes.
This hypothesis was examined in cell-free and whole-cell preparations of L6 rat 
and C2C12 mouse myoblast cell lines using biochemical, immunological, 
immunocytochemical and molecular genetic techniques. Fusion-deficient and 
cathepsin B gene-trapped variants of L6 and C2C12, respectively, and cathepsin B 
promoter gene constructs were also used in the study.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
41
M aterials and Methods
2.1 M aterials
Superose 12 HR 10/30 FPLC columns were purchased from Pharmacia (Uppsula, 
Sweden). The protein assay kit and nitrocellulose membranes were purchased from 
Bio-Rad (Mississauga, ON). Minimal essential medium (a-M EM ), horse and fetal 
bovine sera, gentamycin sulfate, trypsin, ethylenediaminetraacetic acid (EDTA), and 
tissue culture plasticware were purchased from GIB CO (Burlington, ON). Bovine 
serum albumin (BSA), Tween, sodium selenite, Giemsa stain, Biuret’s reagent, Folin- 
Ciocalteau reagent, E-64, pepstatin, 7-amino-4-methylcoumarin, pepsin, egg white 
cystatin, creatine phosphate, N icotinamide-adenine-dinucleotide (reduced), 
Nicotinamide-adenine-dinucleotide-phosphate, glucose-6-phosphate dehydrogenase, 
hexokinase, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), myokinase 
(MK), cathepsins B (CatB), cathepsin D (CatD), N-alpha-CBZ-argininyl-argininyl-7- 
amido-methylcoumarin. H Cl (Z-arg-arg-NHMec), N-alpha-CBZ-phenylalanyl-L- 
argininyl-7-amido methylcoumarin.HCl (Z-phe-arg-NHMec), and hemoglobin (Hb) 
were purchased from Sigma Chemical Co. (St. Louis, MO). The cathepsin B selective 
inhibitor, CA074, was generously provided by Nobuhiko Katunuma (University of 
Tokushima, Japan). Rabbit anti-human liver cathepsin B IgG was prepared as 
previously described (Moin et al. 1992). Rabbit anti-human cathepsin L IgG was 
generously provided by Susan Kane (National Cancer Institute, Bethesda, MD). Texas 
Red-conjugated affinity-purified donkey anti-rabbit (IgG), anti-rabbit IgG and normal 
donkey serum were obtained from Jackson ImmunoResearch (West Grove, PA).
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SlowFade anti-fade reagent was purchased from Molecular Probes (Eugene, OR). The 
enhanced chemiluminescence western blot detection system was purchased from 
Amersham (Arlington Heights, IL).
2.2 Cell Cultures
The differentiating, immortal, rat myoblast cell line, L6, was originally 
established from newborn rat hind limb skeletal muscle by Yaffe (1968), then cloned 
and characterized by Dufresne et al. (1976). L6, L6S, a precocious fusing subclone of 
L6, and L6D3, a nonfusing, 5-azacytidine resistant variant of L6 were obtained from 
the laboratory of Dr. B. Sanwal (University of Western Ontario, London ON). Drug 
resistance in L6D3 reflects an alteration of a component of two target pathways of this 
drug, the de novo pyrimidine pathway and an undefined sequence leading to the 
synthesis of membrane components (Ng et al. 1976).
The differentiating, immortal C2C12 mouse myoblast cell line used in this study 
is a subclone of the C2 mouse myoblast cell line originally established from 18 day- 
old mouse hind limb skeletal muscle by Yaffe and Saxel (1977). The control and 
gene-trapped C2C12 variant clones used in this study are described in Gogos et al.
(1996) and were obtained from the laboratory of Dr. M. Horwitz (University of 
Washington, Seattle, WA). Two gene-trapped variants were used. The first variant, 
RT-27, was trapped in one of the two C2C12 myoblast cathepsin B gene alleles using 
a ROSAPgeo retroviral gene-trap vector. The second variant, RT-11, was trapped in a 
gene other than cathepsin B using the same retroviral gene-trap vector.
The immortal LM mouse fibroblast cell line was purchased from American Type
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Culture Collection (ATCC, Rockville, MD).
2.3 M aintenance and Transfer of Cell Cultures
All cell lines were maintained in an atmosphere of 5% CO2 - 95% air in alpha 
(a -)  MEM supplemented with either 10% heat-inactivated horse or 10% heat- 
inactivated fetal calf sera as well as 4.5 g/L D-glucose and 50 pg/mL gentamycin 
sulfate. In differentiating myoblast cultures, the ratio of fusion-restricted (i.e., 
presumptive) to fusion-capable (i.e., post-mitotic) myoblast populations in the 
myogenic lineage was serum-controlled; medium supplemented with 10% fetal calf 
serum favors the former, while medium supplemented with 10% horse serum favors 
the latter (Yeoh and Holtzer 1977).
All cell cultures used in this study were anchorage dependent and were therefore 
serially passaged using trypsin (Freshney 1987). Trypsinization of differentiating L6 
and C2C12 myoblast cell lines was always conducted prior to alignment and the onset 
of myotube formation. Cells were washed with 37°C citrate saline (15 mM trisodium 
citrate, 134 mM potassium chloride, pH 7.8), trypsinized (0.25% trypsin-EDTA), 
collected, suspended in 5X the volume of serum-containing growth medium, and 
centrifuged at low speed (1500 x g) for 5-10 minutes. The cell pellet was resuspended 
in serum-containing medium and the cells were plated into tissue culture plasticware 
at 104 - 105 cells/mL.
2.4 Cell Cloning
Cells were cloned in 96-well Linbro microtest plates (6 mm) as follows. Cells in
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exponential growth were dissociated from flasks with trypsin, centrifuged, 
resuspended in growth medium at a concentration of 5 cells per mL and plated into 
microtest plates (0.2 mL of the cell suspension/well). The following day, wells were 
examined for single cells and those that in time gave rise to single colonies o f at least 
20 cells were trypsinized and serially cultured into 24 well plates, 6 well plates, 25 
cm tissue culture flasks, and finally 75 cm flasks. These cells were checked for the 
phenotypes of interest and frozen down in a number of vials and stored at -70°C and at 
-195°C as described next.
2.5 Cell Storage
Cells maintained in culture long term can be lost to contamination and 
technical/mechanical failures, and can demonstrate alterations in genotype and 
phenotype. To minimize these problems, cells were first checked for the phenotypes 
of interest, grown and frozen down to provide a stock of frozen cells. As a general 
rule, cell cultures were maintained no longer than 50 generations. After this time, a 
frozen aliquot of the original cell line was thawed, analyzed for phenotypes and used.
To freeze down, cells were washed with citrate saline, trypsinized using 0.25% 
trypsin-EDTA, collected and suspended in 5X the volume of serum-containing growth 
medium, then centrifuged at low speed (1000 x g) for 5 minutes. The cell pellet was 
resuspended at a concentration of 2 x 106 cells/mL in freezing solution consisting of 
70% a-MEM, 10% DMSO and fetal calf serum (v/v). One mL aliquots were 
transferred into Nunc cryotube vials, placed at -20°C for 30 minutes then stored in an 
ultra-cold freezer at -70°C and in liquid nitrogen at -195°C. Approximately one week
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after freezing, sample vials were checked for contamination, cell viability and 
expression of phenotypes of interest. Cells frozen in this manner remained viable 
without loss of or alterations in relevant genotypes and phenotypes for a number of 
years.
2.6 Characterization of Cells in Culture
2.6.A. Population Doubling Time and Saturation Density
The population doubling time (To) and the saturation density (S.D.) were 
determined from growth curves constructed for each cell line. After trypsinization, 
centrifugation, and resuspension, cells were plated into 60 mm tissue culture dishes at 
a concentration of lÔ  to 106 cells per plate and incubated at 37°C. Once plated, the 
number o f cells in each of two dishes was determined at two time points each day 
using a hemacytometer. The cell counts were then plotted on a semi-logarithmic scale 
against the appropriate time point. The population doubling time was calculated 
during exponential growth while saturation density was calculated from the plateau 
phase and expressed as cells/cm2.
2.6.B. Cell Staining and Fusion Index
A quantitative estimation of myoblast fusion, referred to as fusion index (i.e., % 
fusion), was obtained using the procedure of Morris and Cole (1972). Cells were 
plated in tissue culture dishes and incubated at 37°C. At various times after incubation 
the medium was removed, cells were washed with 0.4% citrate saline (pH 7), and 
fixed by addition of 95% ethanol. After drying, the cells were stained with Giemsa 
(6%, 20 min.), rinsed with tap water, air-dried, and examined with an inverted
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microscope at 100 or 200 X magnification. The total number of nuclei and the number 
of nuclei within myotubes in 10 fields were determined and the ratio of the latter to the 
former expressed as a percentage. A cell was scored as a myotube if it contained 3 or 
more nuclei within the same cell membrane. Since binucleate cells were not included 
in myotube counts, estimates of fusion index usually reflect minimum levels.
2.7 Preparation and Collection of Cells and Conditioned Medium
Cells were routinely maintained in 25 cm2 culture flasks, but were passaged to 75 
cm2 culture flasks to provide sufficient numbers for plating in 100 mm tissue culture 
dishes. Depending on the cell line and the experiment, dishes were plated with 
between 105 to 5 x 105 cells and incubated at 37°C. At each appropriate time point 
(i.e., day/phase of growth), medium was decanted and examined for cellular debris. 
Cells on the surface of the dishes were collected on ice in 1 mL cold (4°C) phosphate 
buffered saline (PBS: 0.027 mM KC1, 1.5 mM KH2P 04, 150 mM Na2H P047H20, and 
140 mM NaCl, pH 7.6) using a rubber policeman. Cells were then diluted in cold PBS 
and centrifuged at 1000 x g for 5 minutes. The cell pellet was suspended in 10 mL 
cold PBS and centrifuged again at 1000 x g for 5 minutes. After two additional 
PBS/centrifugation cycles, the final pellet was stored at -20°C. Prior to enzyme 
assays, cell pellets were thawed and resuspended in homogenization buffer (135 mM 
KC1, 0.1 mM ETDA, 0.1% Tween, and 15 mM KH2P 0 4. pH 6.0). Cell suspensions 
were then homogenized on ice with a Brinkman Polytron PT-10 (Brinkman 
Instruments, Oakville, ON) on setting 4 for three, 10 second pulses. Homogenates 
were clarified by microcentrifugation for 5 minutes at 4°C using a Fisher Model 59
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microfuge.
For coordinate analysis of protease activities present in and secreted from cells 
during their growth, medium on plates was replaced with serum-free, defined medium, 
24 hours prior to collection (Dufresne et al. 1993). This transfer did not affect the 
viability, growth parameters or relevant phenotypes of any of the cell lines examined. 
Moreover, all cell lines were anchorage-dependent and the proportion of cells 
liberated into regular or defined medium, even at saturation, was negligible. At each 
time point, the serum-free medium added to cells 24 h prior to collection was 
removed, centrifuged in the cold at 1500 x g for 5 minutes and either was used directly 
or was concentrated by Amicon filtration. Concentration of medium was performed in 
a 4°C coldroom using N2 gas positive pressure filtration through a Ymb3 Amicon filter 
(selective for molecular weights greater than 10 kDa). Routinely 20 fold 
concentration was achieved (e.g., 40 mL to 2 mL). In this study, fractions prepared 
from cell homogenates and their corresponding media are referred to as cell or 
intracellular, and media or extracellular fractions, respectively.
2.8 Enzyme Activity Assays
2.8.A. Cathepsin B Activity and Cathepsin L-type Activity
Cathepsin B and cathepsin L-type activities were measured using the appropriate
flourometric, 4-methylcoumaryl-amide substrates according to a modified procedure 
of Barrett and Kirschke (1981) (Jane and Dufresne 1994). A 500 pL aliquot 
homogenate sample (10.0 fig protein diluted in 0.1% Brij 35 solution) was 
preincubated for 5 minutes at 37°C with 250 pL of activation buffer (cathepsin B: 352
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mM KH2PQ4 , 48 mM Na2HP04, 4 mM disodium EDTA, and 8 mM dithiothreitol, pH 
6.0; cathepsin L-type: 340 mM sodium acetate, 60 mM acetic acid, 8 mM 
dithiothreitol, and 4 mM disodium EDTA, pH 5.5). The reaction was started by the 
addition o f 250 \xL of 0.02 mM substrate solution (cathepsin B: Z-arg-arg-NHMec, or 
Z-phe-arg-NHMec; cathepsin L-type: Z-phe-arg-NHMec). After 10 minutes 
incubation at 37°C, reactions were terminated with the addition of 1 mL stopping 
reagent (100 mM sodium monochloroacetate, 30 mM sodium acetate, and 70 mM 
acetic acid, pH 4.3). Since both cathepsin B and L-type proteases recognize the Z- 
phe-arg-NHMec substrate, cathepsin B activity was measured with Z-phe-arg-NHMec 
in the presence and absence of 10 pM of the cathepsin B selective inhibitor CA074 (1 
x 10'7 M). Cathepsin L-type activity was measured with Z-phe-arg-NHMec in the 
presence of cathepsin B selective inhibitor, CA074 (1 x 10'7M) (Towatari et al. 1991). 
The fluorescence of free aminomethylcoumarin in each reaction tube was measured at 
room temperature with an excitation wavelength of 370 nm and an emission 
wavelength of 460 nm with a Turner Model 430 Spectrofluorometer (G.K. Turner 
Associates, Palo Alto, CA). Fluorescence readings were standardized with 0.5 (iM 7- 
amino-4-methyl-coumarin standard set at 1000. The Spectrofluorometer was adjusted 
such that 1000 arbitrary units corresponded to the release of 1 nmol of product. One 
milliunit of proteolytic activity was defined as the quantity of enzyme releasing 1 
nmol of aminomethylcoumarin per minute.
Levels of acid/pepsin activatable cathepsin B and L-type (i.e. latent procathepsin) 
activity were determined in extracellular fractions using a modified procedure o f Mort 
et al. (1981) (Jane and Dufresne 1994). For each reaction, 150 pL of conditioned
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media was activated with 30 pL of 0.5 mg/mL pepsin in an acid buffer (0.8 M 
anhydrous sodium acetate, pH 3.8) at 40°C for 1 hour. The pH was adjusted to 6.0 
with 60 pL of 0.2 M potassium phosphate buffer, pH 9.0. The reaction was initiated 
by adding 250 pL of substrate, terminated with 1 mL of stopping reagent, and the 
liberated 7-amino-4-raethylcoumarin measured as described above.
2.8.B. Cathepsin D Activity
Cathepsin D activity was measured in intracellular and extracellular fractions 
using 8 .0 % w/v hemoglobin as substrate according to a modified version of the 
standard general protease assay of Turk (Turk et al. 1984). In a final reaction volume 
of 1 mL, 500 pL of diluted sample was added to 250 pL of acetic acid assay buffer 
(1.35 M acetic acid, 20 mM NHSO4, pH 3.5;) and 250 pL of bovine hemoglobin 
substrate (8.0% w/v hemoglobin). The reaction was started by incubation of the 
reaction tubes at 37°C. After 60-120 min of incubation the reaction was terminated 
with the addition of 2 mL of 3% (w/v) trichloroacetic acid which precipitated non­
digested hemoglobin and dissolved liberated peptide fragments. After an additional 
15 minute incubation period, this reaction mix was centrifuged for 10 minutes at 4000 
rpm and to 1 mL of clear supernatant was added to 2 mL of modified biuret reagent 
and allowed to stand for an additional 15 minutes at room temperature. Absorbance at 
750 nm was determined after the addition of 600 pL Folin-Ciocalteau reagent. One 
Anson Unit is defined as the amount of protease able to liberate, through degradation 
of hemoglobin, 1 pmol of free tyrosine per minute as measured by Folin-Ciocalteau 
reagent. [There is a linear relationship between absorbance and increasing 
concentrations of a tyrosine standard.]. All activities were measured concurrently in
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the presence and absence of the microbial pentapeptide, Pepstatin A, and represent 
total activity minus Pepstatin insensitive activity measured concurrently from a second 
aliquot of the sample. Pepstatin strongly inhibits cathepsin D activity prepared from a 
variety of sources including swine liver, rabbit liver and human liver, bovine lung, 
rabbit lung, rabbit alveolar macrophages and porcine brain.
2.8.C Creatine Phosphokinase (CPK) Activity
The enzyme assay for CPK activity was performed using the procedure of 
Bergmeyer (1974). Cell homogenates were prepared as outline in section 2.7 and were 
diluted to give a standard working concentration of 1 pg/pL. One hundred microliters 
of clarified cell homogenate was then added to 950 pL of assay buffer (0.2M Imidizol; 
0.04M D-Glucose; 0.02 M Mg Acetate; 0.008M NADP; 0.01M ADP; 0.1M AMP; 
0.35M Phosphocreatine; 0.1 M MESH) along with 20 pL of enzyme solution (53 units 
Hexokinase; 52 units Glucose-6 -phosphate Dehydrogenase) and incubated at room 
temperature for 5 minutes. After incubation, the reaction mixture was assayed for 
CPK activity using a spectrophotometer set to 340 nm. The absorbance values were 
recorded for 2 0  minutes and were plotted against time to yield a slope used to 
determine the rate of the reaction. One unit of CPK activity was defined as that 
amount of protein required to transfer 1 .0  pmole of phosphate from phosphocreatine to 
ADP per minute at pH 7.4 and 30°C.
2.8.D. Myokinase (MK) Activity Assay
The MK activity assay was performed as outline for CPK (see section 2.8.C) 
except that the standard stock solution was diluted to 0.5 pg/pL of the total protein 
content. One enzyme unit is defined as that amount of protein that will phosphorylate
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activity levels in the cell supernatants, it was necessary to dilute the original stock 
solution to a concentration that would allow for the reaction to be measured in a 
fifteen minute time period.]
2.8.E. Lactate Dehydrogenase (LDH) Enzyme Activity Assay
The enzyme assay for LDH activity was performed using the procedure of 
Bergmeyer (1986). Cell homogenates were prepared as outline in section 2.7 and were 
diluted to give a standard working concentration of 0.5 pg/pL. 100 pL of clarified cell 
homogenate was then added to the reaction mix [3.0 mL of HST buffer (700 mg 
K2HPO4; 90 mg KH2PO4; 9.9 mg Na pyruvate) + 50 pL of NaHCCH solution (14 mg 
NADH-Na2 ; 15 mg NaHCCb)] and incubated for 5 minutes at room temperature. At 
the end of the incubation period, the reaction mix was assayed for LDH activity by the 
reduction of NADH to NAD. One unit of LDH enzyme activity is defined as one unit 
mole that will reduce 1.0 pmole of pyruvate to lactate per minute at pH 7.5 and 37°C.
2.9 Fast Protein Liquid Chromatography (FPLC) Analyses
2.9.A. FPLC Selectivity Curve and Molecular Mass Determination
Molecular mass standards were run on a Superose HR 10/30 FPLC column and 
their elution volumes recorded. Blue Dextran (V0), as well a bovine albumin (66.0 
kDa), ovalbumin (45.0 kDa), carbonic anhydrase (29.0 kDa), and cytochrome C (12.4 
kDa), were used to construct a selectivity curve for the approximation of molecular 
mass. Separation coefficients (Kav) were calculated using the following formula:
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K av = Ve - V0 /  V , - V0 
where Ve = the elution volume, V0 = the void volume, and V t = the total volume.
2.9.B. FPLC Fractionated Homogenate
After centrifugation (12,000 x g, 5 min), 100-200 mg of protein from the 
appropriate cell or media fraction was loaded in 500 p.L of homogenization buffer 
(135 mM potassium chloride, 0.1 mM EDTA, 0.1% Tween 80, 15 mM potassium 
phosphate, pH 6.0) on a Superose 12 HR 10/30 FPLC column (Pharmacia, Upsala, 
Sweden). Fractions were eluted in column buffer (25 mM KC1, 0.1 mM EDTA, 10% 
glycerol, 15 mM K3PO4, pH 6.0) at a flow rate of 0.5 mL/min. Absorbance during 
elution was monitored using a Bio-Rad optical unit at a UV wavelength of 280 nm. 
Elution profiles were recorded on a Bio-Rad Chart Recorder at a chart speed of 0.5 
cm/min. 500 pL fractions were collected with a Bio-Rad Fraction Collector and 
fractions were stored on ice until assay.
2.9.C. Protease Assay of FPLC Fractions
For assays of cathepsins B and L-type activities using their respective 
flouromelric substrates, the procedures and buffers used were identical to those 
described for assay of unfractionaled homogenates (see section 2.8.A). In brief, 50 pL 
of intracellular fraction or pepsin/acid treated extracellular fraction was diluted with 
450 pL of 0.1 % Brij solution in distilled water. Diluted fractions were then pre­
incubated in the presence or absence of the cathepsin B selective inhibitor, CA074, or 
the cysteine protease inhibitor, E-64, for 5 minutes at 37°C with activation buffer at 
the appropriate pH (cathepsin B, pH 6.0; cathepsin L-type, pH 5.5). The reactions
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were started by the addition of 250 pL of Q.02mM stock substrate. After 10 minutes 
incubation at 37°C, the reactions were terminated by the addition of 1 mL stopping 
reagent. Blank and sample tubes were prepared and the fluorescence of free 
aminomethylcoumarin in each was measured at an excitation wavelength of 370 nm 
and an emission wavelength of 460 nm.
Cathepsin D activity was measured using hemoglobin as substrate and in the 
presence and absence of the aspartyl protease selective inhibitor pepstatin according to 
the procedures for unfractionated homogenates (see section 2.8.B).
2.10 Western Blot Analysis of Cathepsin B and Cathepsin L
Western blot analyses were performed according to the methods described in 
Moin et al. 1992.
2.10.A. Preparation of Cell and Media Samples
Cells were grown and collected along with their media as described in section 2.7. 
Both cells and media fractions were stored at -80°C until further use. Three times the 
volume of SME (0.25M sucrose; 0.025 M MES and 0.001 M EDTA) was added to 
frozen cell pellets and the pellets dissociated by dipping 3 times in liquid nitrogen. 
Thawed cell pellets were sonicated 2 times at 15 sec intervals. The resultant cell 
homogenates and the thawed media samples were clarified by centrifugation at 1 2 0 0 0  
X g for 10 minutes. After centrifugation, the sample supernatants were concentrated to 
a volume of 200 pL or less using YM5 or YM10 Amicon filters. The protein 
concentration of each concentrated sample was determined and adjusted to a 80-100 
ng/ 30 fiL using either 2X or 5X sample buffer (1:1).
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2.10.B. Polyacrylamide Gel Electrophoresis
Polyacrylamide gel electrophoresis (PAGE) was performed by a modified method 
of Laemmli (1970) using 4% (w.v) stacking (13.5 mL distilled water; 10 mL 1.5 M 
Tris-HCl, pH 8 .8 ; 0.4 mL 10% SDS; 16 mL acrylamide:bis; 10% (NH4)S20 4 and 10- 
12% (w/v) resolving (6.1 mL distilled water; 2.5 mL Tris-HCl, pH 6 .8 ; 0.1 mL 10% 
SDS; 1.3 mL acrylamide:bis; 0.05 10% (NH4 )S20 4 ; 0.005 TEMED) gels. Samples 
and standards (Bio-Rad Biotinylated and Rainbow) were first mixed with an equal 
volume of sample buffer (125 mM Tris-HCl, pH 6 .8 , 10%bME, 20% glycerol, 4% 
SDS, and 0.02% bromophenol blue) then heated in a boiling water bath for 5 minutes. 
After application to the gel, samples were electrophoresed at 25 volts (50 mA/gel) 
until the samples migrated through the stacking and resolving gels and the dye front 
reached the bottom of the gel.
2.10.C. Transfer to Nitrocellulose Membrane
A nitrocellulose membrane and pads were presoaked in transfer buffer (3.3 g/L 
Tris-HCl and 14.4 g/1 glycine) and used to form a stack with the gel. Gels were then 
electroblotted onto the nitrocellulose membrane in transfer buffer overnight at 30mA, 
then for 1 hour at 90 mA. After electroblotting, the gel was stained with 0.2% 
Coomasie Brilliant Blue G-250 (in 10% (v/v) acetic acid and 40% (v/v) methanol) to 
visualize protein transfer.
2.10.D. Western Blotting with Enhanced Chemiluminescence
After electroblotting, each nitrocellulose membrane was placed in a glass dish 
with distilled water and washed by shaking for 10 minutes. The washed membrane
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was blocked with the commercial blocking reagent Blotto for 1.5 hours or overnight at 
4°C then washed 3 times for 10 minutes in TTBS (20 mM Tris; 500mM NaCl, pH 7.5; 
0.2%Tween 20). The membrane was then incubated for 2 hours with TTBS 
containing the first antibody [for cathepsin B: 20 pL of rabbit anti-human liver 
cathepsin B stock antibody in lOOmL milk/TTBS solution (i.e. 1:5000); for cathepsin 
L: 60 pL of mouse anti-human liver sera cathepsin L stock antibody (NIH) (i.e. 
1:1600)] with shaking. After incubation in primary antibody, the membrane was: a) 
washed 4 X 10 minutes in TTBS, b) incubated for 30 minutes with biotinylated 
secondary antibody diluted 12 pL/lOOmL (v/v) in TTBS, c) washed again (2X) in 
TTBS for 10 minutes each, and d) exposed to secondary antibody [10 pL of Goat to 
rabbit Horseradish Peroxidase labeled second antibody (Bio-Rad) stock in 100 mL 
milk/TTBS solution (i.e. 1:10000) ] for 1 hour with shaking. After incubation with 
secondary antibody, the membrane was washed 4 X 10 minutes in TTBS and then 
overnight in TTBS at 4°C.
Detection was performed in a darkroom using enhanced chemiluminescence 
(ECL) reagents from Amersham (Arlington Heights, IL). Briefly, ECL reagents were 
mixed 1:1 (total 25 mL) and poured onto the blot in a dish and rocked for 1 minute. 
The blot was drained, wrapped in plastic wrap and exposed to Hyperfilm ECL 
(RPN.2103) for 2 seconds to 5 minutes. The film was then developed using a Kodak 
X-ray Film Developer.
2.11 Northern Blotting for Cathepsin B mRNA
Total RNA was collected and northern blot analyses were done according to the
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methods of Moin et al. 1989.
2.11.A. Isolation of Total RNA
Total cellular RNA from L6 S and L6D3 myoblast cell lines was isolated from 
cultures lysed with 5 mL/100 mm dish of TRIsol (Life Technologies). After passing 
the cell lysate through a syringe several times, the samples were incubated for 5 min at 
15-30°C to allow dissociation of nucleoprotein complexes. 0.2 mL of chloroform per 1 
ml, of TRIsol reagent was added and the samples were shaken vigorously for 15 
seconds. The shaken samples were incubated at 15-30°C for 2-3 minutes. After 
incubation the samples were centrifuged at 12,000 x g for 15 minutes at 4°C. The 
aqueous phase was transferred to a fresh tube from which RNA was precipitated using 
0.5 mL of isopropyl alcohol per 0.5 mL of TRIsol initially used. RNA containing 
samples were incubated at 15-30°C for 10 minutes and centrifuged at 12000 x g for 10 
minutes at 4°C. The resultant RNA pellet was washed with 1 mL of 75% ethanol by 
centrifuging at 7500 x g for 5 minutes at 4°C. The final RNA pellet was air-dried for 
5-10 minutes and dissolved in RNase free autoclaved water and stored at -80°C.
To ensure that the RNA sample was free of DNA, it was treated with 2 pL of 
DNase (10 U/pL) at 37°C for 30-45 minutes, then at 94°C for 10 minutes. After 
heating, the RNA was reprecipitated by incubating the sample with 1 mL of 
isopropanol for 10 minutes followed by a 10 minute centrifugation at 12,000 X g. The 
final RNA pellet was resuspended in 1 mL of 75% ethanol and centrifuged at 7500 x g 
for 5 minutes at 4°C. The ethanol-washed pellet was allowed to air dry and stored at -  
80°C in 10-15 pL of RNase-free distilled water.
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2.11.B Agarose Gel Electrophoresis
All apparatus used to prepare and cast the agarose gel was washed with RNase- 
free water and autoclaved. To cast a 180 mL (total volume) gel. 1.45 g of agarose were 
added to 132.5 mL of RNase-free water and heated in a microwave until the agarose 
frothed. After the solution was cooled, 36 mL of 5 X formaldehyde gel running buffer 
(1M MOPS, pH 7.0; 3M NaAc, pH 7.0; 0.5M EDTA, pH 8.0; 87.7 mL RNase-free 
water) were added along with 10 mL of 37% formaldehyde. After cooling, the solution 
was poured into clean gel casting equipment, covered with a box and allowed to 
polymerize for 30-60 minutes at room temperature.
Prior to electrophoresis, the sample was heated 55°C-65°C for 10 minutes to 
ensure that the RNA is in solution. For each gel, both experimental RNA and standard 
RNA ladder samples were prepared (4.7 pL of RNA (10-30 pg) + 2.0 pL of 5X 
formaldehyde gel running buffer + 3.3 pL of 37% formaldehyde + 10 pL of 
formamide), and incubated at 65°C for 10 min. After incubation, 2.0 pL of stock 
loading buffer (50% glycerol; ImM EDTA; 0.4% bromophenol blue; 0.4% xylene 
cyanol) and 1.0 pL of ethidium bromide (1 pg/pL) were added to the samples. The 
samples were incubated at room temperature for 5 minutes to promote intercalation of 
the dye. At the same time, each gel was soaked in IX formaldehyde running buffer (50 
m l ,  5X buffer into 200 mL RNase free water) contained within the gel box. After 
incubation, the samples were loaded onto the soaked gel, and the gel was run at 70 
volts for 1 -2  hours.
2.11.C. Transfer of RNA
All transfer apparatus was first washed in RNase-free water. The nitrocellulose
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(transfer) membrane was immersed first in distilled water and then in transfer buffer ( 
10 mM Tris; 1 raM EDTA) for 5 minutes. Twenty sheets of dry, GB004 blotting paper 
(thick) were placed in the tray followed by 4 sheets of dry GB002 (thin) and 1 sheet of 
GB002 blotting paper. The transfer membrane was placed on top of this blotting stack, 
followed by the agarose gel, ensuring that no air bubbles were visible between the gel 
and the membrane. The top surface of the gel was wetted with transfer buffer. Three 
sheets of presoaked GB002 blotting paper were then placed on top of the gel. The 
“buffer tray” was secured and filled with transfer buffer; transfer was initiated by 
placing the “buffer wick” across the top of the stack. The stack was covered with 
plastic wrap to prevent evaporation and transfer continued overnight at room 
temperature. After transfer, the gel was examined on a UV light box to ensure that all 
of the RNA was transferred from the gel to the blot. The blot was then UV 
crosslinked.
2.11.D. Northern Blot Hybridization using DIG-labeled RNA Probe
Northern blotting was performed using the Genius System. The blot was 
prehybridized by placing it in a hybridization bag or tube containing 20 mL of 
hybridization buffer/100 cm2 of membrane surface, at 50°C for at least 1 hour 
[standard buffer (25 mL 5X SSC; 2.0% blocking solution; 0.1% N-lauroylsarcosine; 
50% formaldehyde; 5ml RNase-free water)]. During this time, the probe was thawed, 
heat denatured for 10 minutes at 6 8 °C, then diluted in hybridization buffer to a 
concentration of 50 ng/mL for an RNA probe. [For a DNA probe, 25 ng/mL is 
suggested.] When prehybridization of the blot was completed, the original 
hybridization buffer was replaced with hybridization solution containing the DIG-
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labeled RNA probe. [Dig labeling was done using a kit from Boehringer M annheim  
such that the pLC343 plasmid was cut at the Kpnl site in exon 4 and run-off 
transcription was done at the 3’-end of the cDNA.] After the addition of the RNA 
probe, the blot was incubated overnight at 6 8 °C to facilitate hybridization. The next 
day, the hybridization solution containing the probe was poured into a new tube and 
stored at -80°C for future use. The membrane was washed twice for 15 min per wash 
in 2X wash solution (2X SSC, 0.1% SDS) at room temperature, and then two more 
times in 0.5X wash solution (0.5X SSC, 0.1% SDS).
2.1 I.E. Detection
The final washed membrane was equilibrated in washing buffer (0.1 M maleic 
acid, 0.15 M NaCl, pH 7.5 + Tween-20, 0.3% (w/v)) for 1 minute, then blocked by 
gently agitating it in blocking solution (0.1 M Maleic Acid, 0.15 M NaCl, pH 7.5 + 
Blocking reagent, 1% (w/v)) for 30-60 minutes. The anti-digoxigenin-AP conjugate 
was diluted to 150 mU/mL (1:20,000) in blocking solution (1 pL in 20 mL o f blocking 
buffer). The membrane was incubated with approximately 5 mL of diluted antibody 
conjugate solution for 30 minutes. After antibody incubation, unbound antibody 
conjugate was removed by 2 X 15 minute washes with washing buffer, and the 
membrane was equilibrated for 2 minutes with 20 mL of detection buffer (100 mM 
Tris-HCL, 100 mM NaCl, pH 9.5). During equilibration, the CDP-star was diluted 
1:100 in detection buffer. After equilibration, the membrane was placed between two 
sheets of acetate and using a sterile pipette, approximately 5 mL (per 100 cm2) of the 
chemiluminescent substrate was spread evenly over the entire surface of the 
membrane making sure there were no air bubbles. After 5 minutes, the excess liquid
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was wiped away, and the blot was exposed to Hyperfilm for 15 sec -  5 minutes at 
room temperature and developed using a Kodak developer.
2.12 Immunocytochemistry
Intracellular cathepsin B was localized using a modification of the general 
immunocytochemical methodologies previously described by Willingham (1990). 
Briefly, cells were seeded on round class coverslips within wells o f a 48 well tissue 
culture tray containing differentiation medium (i.e., a-MEM + 10%HS). Cells were 
plated at concentrations that would allow them to reach the appropriate stage of 
growth/differentiation in culture before fixation. Cells were washed 3X with 
phosphate buffered saline (PBS: 0.027 mM KC1, 1.5 mM KH2PO4, 150 mM 
Na2HPC>4 .7 H2 0 , 140 mM NaCl, pH 7.4) and then fixed with either 3.7% 
formaldehyde for 10 minutes (LM fibroblasts) or with 100% cold methanol for 2 
minutes (myoblasts). The fixed cells were washed 3X with PBS and incubated with 
0.2% bovine serum albumin (BSA) for 45 minutes to block nonspecific binding sites. 
The blocked cells were then washed 3X with PBS buffer containing 1% Saponin. 
After washing, the cells were incubated in 150 pL of the primary antibody (alpha-anti- 
human liver cathepsin B diluted 1:50 in PBS-0.1% Saponin) for 1 hour in the dark. 
After removal of the primary antibody, the cells were washed 6 X for 10 minutes each 
with PBS-0.1% Saponin. The cells were then incubated in a second blocking reagent 
(5% normal donkey serum in PBS-0.1% Saponin) along with secondary antibody 
(Texas Red-conjugated affinity-purified donkey anti-rabbit IgG) at a dilution of 1:40 
for 1 hour. After 6 X rapid washes with PBS-0.1 % Saponin, the cells were fixed with
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the same fixative used initially (i.e., either 3.7% formaldehyde or 100% methanol). 
The fixed cells were washed 3X with PBS-0.1% Saponin, then dipped several times in 
distilled water and left to air-dry at room temperature. One drop of anti-fade reagent 
was applied to each dry coverslip. Finally, the coverslip was mounted and sealed using 
commercial nail polish. Cells on the sealed coverslips were observed using a Ziess 
LSM 310 confocal microscope and viewed at 200 X magnification. [Note: In these 
analyses, two controls were used: a primary antibody control (Pri-immune rabbit IgG 
diluted 1/80 in PBS), and a secondary antibody control (i.e., no primary).]
2.13 Commercial Cysteine Protease Inhibitor Analysis
L6 S cells were seeded at 1 x 105 cells per 60 mm dish in alpha MEM + 10% horse 
serum. After 24 hr of growth, the medium was replaced with alpha MEM + 10% 
horse serum supplemented with either 5 pM, 10 pM, or 50 pM of each of the 
following commercial cysteine protease inhibitors in DMSO: 1) CA074, a 
nonpenetrating cathepsin B selective inhibitor, 2) CAQ74Me, a penetrating cathepsin 
B selective inhibitor, 3) E-64, a nonpenetrating cysteine protease inhibitor, and 4) Z- 
phe-ala-CHF2, a short peptide cysteine protease inhibitor. Medium was replaced on 
control (i.e., containing DMSO) and inhibitor-treated (i.e., containing inhibitor in 
DMSO) plates every 48 hours. Every 24 hours starting with day 2, cells were fixed 
with ethanol, stained with Giemsa and examined with an inverted microscope.
2.14 Cell Transfection of Cathepsin B cDNA
Plasmid preparations, cell transfections, luciferase and fl-galactosidase assays
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were performed according to the methods of Berquin et al. 1996.
2.14.A. Plasmid Preparation
pGL2-reporter plasmids containing the luciferase cassette and various restriction 
length fragments of a 2.2 kb cathepsin B promoter sequence upstream of the presumed 
start site o f exon 1 were purified from E. coli bacteria as described in the Promega, 
Wizard Midipreparation DNA Purification Kit. A 500 mL Gibco bacterial culture 
(Yeast broth) was inoculated with 0.5 -  1.0 mL of the appropriate bacterial strain. 
After 24 hours of growth, this culture was used to inoculate several 2L flasks of 
growth medium. After 48 hours of growth, approximately 100 mL of cells were 
peleted by Sorval centrifugation at 10000 X g for 10 min at 4°C. The cells were 
resuspended in 3 mL of resuspension solution (50 mM Tris-HCl, (pH 7.5); 10 mM 
EDTA; 100 ug/mL RNaseA) and 3 mL of cell lysis solution (0.2 M NaOH + 1% 
SDS). The solutions were mixed by inverting the tube 4 times and incubated at 4°C for 
3 minutes. Three mL of neutralization solution (1.32 M potassium acetate) was added. 
After mixing, the mixture was incubated for 10 min a 4°C, then centrifuged at 14000 
X g for 30 minutes at 4°C. The supernatant was poured into a fresh tube taking care to 
avoid the white precipitate. Ten mL of resuspended resin was mixed into the 
supernatant and the DNA/resin mixture was then added to a Midicolumn. A vacuum 
was applied to pull the resin into the Midicolumn and the column was washed with 30 
mL of washing solution (80 mM potassium acetate, 8.3 mM Tris-HCl, (pH 7.5); 40 
uM EDTA + 55% ethanol (v/v)) for 30 min. The resin was dried by continuing to 
draw a vacuum for 30 sec after the solution had been pulled through the column. The 
Midicolumn was separated from the reservoir by cutting transferred to a 1.5 mL
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microcentrifiige tube, and centrifuged at 10000 X g for 2 minutes. The Midicolumn 
was then transferred to a new 1.5 mL centrifuge tube containing 300 pL of preheated 
sterilized water. After 1 min the tube was centrifuged at 10000 X g for 20 sec to elute 
the DNA. To eliminate fine resins, the DNA sample was recentrifuged for 5 min. The 
final supernatant was carefully transferred to a new 1.5 mL microfuge tube and stored 
at 4°C or at -20°C.
The purity of the DNA preparation was checked by restriction enzyme digestion 
using SST1, ethidium bromide intercalation and 0.8% agarose gel electrophoresis. 
Briefly, 5 pL of DNA plasmid (0.5 pg/pL) was linearized overnight using 1.2 pL of 
the restriction enzyme, SST1, dissolved in 11.8 pL of distilled water and 2 pL of 
buffer (total volume/sample = 20 pL). The sample was prepared for electrophoresis 
by mixing 20 pL of sample with 5 pL of sample loading buffer (40% sucrose; 0.25% 
bromophenol blue; 0.25% xylene cyanol) and ethidium bromide (1 pL of a lOmg/mL 
stock). Samples were then run with a DNA ladder standard (10 pg) on a 0.8 % 
agarose gel prepared in TBE buffer (50 mM TRIS.HC1 + 70 mM boric acid + 1 mM 
EDTA) at 50 volts for 2 hour. Gels were photographed and the positions of DNA 
sample bands were compared to those for a lkb DNA ladder standard Sigma. The 
pGL2-basic vector was also purified in this manner.
2.14,1, Transfection
One day before transfection, L6 S and D3 cells were seeded in a-M E M  
supplemented with 10% horse serum in 12 well plates at a concentration of 4 x 104 
cells/ well. [NOTE: For differentiating myoblasts, it is important that transfections be 
carried out before the onset of fusion when cells are between 40 - 60% confluent.] On
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the day of transfection, the DNA/Lipofectin mixture was prepared as follows: 
Solution A: 4 pL of Lipofectin + 50 pL of Alpha MEM (supplemented with 2% HS) 
was added by gentle shaking to Solution B: 25ng of pCMVLacZ + an equimole of test 
plasmid in 50 pL of Alpha MEM + pUC19 as a carrier to make up the difference in 
construct size. This Lipofectin/DNA mixture was mixed gently at room temperature 
and incubated for 30 minutes. During this time, the cells were washed twice with pre­
warmed PBS (37°C). For each transfection, 0.9 mL of alpha MEM + 2% HS, then 100 
pi. of Lipofectin/DNA mixture were gently added to the cells. After 24 hours of 
incubation at 37°C, the transfection medium was replaced with 1.5 mL of alpha MEM 
supplemented with 10% horse serum. The cells were incubated for an additional 24 
hours, examined under the microscope then lysed. Lysis involved aspiration of the 
medium from cells, gentle washing with PBS (37°C), and addition of 100 pL of lysis 
buffer. Cells were then scrapped with a rubber policeman, transferred to an 
Eppendorph tube and centrifuged for 5 sec at 12000 X g to remove cell debris. Cell 
pellets were then frozen at -20°C until assayed for luciferase and B-Galactosidase 
activities
2.14.C. Luciferase and B-Galactosidase Assays
Cell lysates were assayed for luciferase activity using Promega’s Luciferase 
Assay System and for B-galactosidase activity using Clonetech’s LumiGal B- 
galactosidase Detection Kit. Both activities measured using a MicroLumat LB96 P 
luminometer (EG&G Berthold) and W indow  software. For luciferase assays, 10 pL 
of cell extract was placed in a microtiter plate and 50 pL of luciferase assay reagent 
was injected. Light produced was measured as a 20-s integral after a delay of 5
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seconds. For B-galactosidase assays, 5 u.L of cell extract was mixed with 33 pL of 
LumiGal reaction buffer and incubated at room temperature for 1 hour. Fifty pL of 
LumiGal chemiluminescence accelerator was injected and light produced was 
measured as a 5-s integral after a delay of 15 seconds. The delay and measurement 
time were chosen based on the recommendations of the assay kit manufactures, and 
reflect differences in the kinetics of product formation by both enzymes. Results were 
measured as relative luciferase light units (RLU), normalized by B-galactosidase 
activity (to correct for variations in transfection efficiency and cell lysate preparation), 
and expressed as a percent of the activity obtained with the pGL-2 control plasmid, a 
positive control plasmid where the luciferase cassette is under the control o f the SV40 
early promoter and enhancer. Since mammalian cells have background B- 
galactosidase activity, mock transfected cell lysates (transfected with carrier DNA) 
were assayed and this value was used to correct B-galactosidase RLU readings. Thus, 
results were calculated using the following formula:
Relative luciferase activity = [LT / (BT-BM)] / [Lc / (Bc-BM)]
Where L is luciferase RLU and B is B-galactosidase RLU, and the subscript indicates 
the transfection sample (T = test plasmid, M = mock-transfected, C = pGL2-Control).
2,15 Protein Determination
Protein content was determined according to a modified version o f Bradford 
(Bradford 1976; Jane and Duffesne 1994). This assay is based on the linear colour 
change of Bio-Rad Coomassie brilliant blue G-250 dye in response to increasing 
concentrations of protein. When the dye binds to protein, there is a shift in the 
maximal absorption from 465 nm to 595 nm. The standard used for determination o f
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
66
protein concentration was bovine serum albumin. This was prepared by dissolving 29 
mg of BSA in 10 mL of nano-pure water. Fifty pL of this stock was then added to 1.4 
mL of nano-pure water to give a second stock concentration of 100 pg/mL BSA. One 
mL of this solution was diluted with 4 mL water to give a working concentration of 20 









2 100 700 200
3 150 650 200
4 200 600 200
5 250 550 200
8 400 400 200
12 600 200 200
standard blank 0 800 200
cell sample 30 770 200
cell sample blank 30 770 200
medium sample 150 650 200
medium blank 150 650 200
Cell samples were suspended in homogenization buffer; in this case the sample
blank was homogenization buffer. The medium sample blank was fresh serum free 
medium. Standards and samples were analyzed with a visible light wavelength of 595 
nm with a Sargent-Welch PU 8610 spectrophotometer.
2.16 Reproducibility of Results
Each result represents the mean of at least three separate experiments conducted in 
triplicate. Standard errors of the mean were computer generated using Microsoft Excel 
and are indicated in tables and figures. Calculations of students t-tests are described in 
Mendenhall et al (1974) and were computer generated using Sigmaplot.
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Results
3.1 The Expression of Cathepsin B Activity in Differentiating Myoblast Cell Lines
3.1 .A The Expression of Cathepsin B Activity follows a “Down-Up” Pattern 
during Myogenesis. The expression of muscle-specific proteins during 
skeletal muscle cell differentiation is temporally related to the fusion of myoblast cells 
into syncytial myotubes (Dufresne et al. 1976). However, fusion-related increases also 
occur for proteins that are not specific to muscle (De La Haba et al. 1968). There is 
evidence that the lysosomal cysteine protease, cathepsin B, falls into this latter 
category (Bird et al. 1981; Bechet et al. 1991; Gogos et al. 1996). However, most of 
this evidence reflects analysis restricted to comparisons between nonfused (i.e., 
myoblasts) and fused (i.e., myotube) cell populations. Since myogenesis in vivo and in 
vitro is a dynamic process involving division, migration, alignment, adherence, and 
fusion of cells, the significance of such comparative studies is limited. This defined 
the initiation site of my research: to establish the pattern of expression of cathepsin 
B activity throughout myogenesis. The two immortal, myoblast cell lines I chose to 
study, L6  rat (Yaffe 1968) and C2C12 mouse (Yaffe and Saxon 1977), are arguably 
the most researched and published in vitro models for myogenesis.
Myoblasts were plated in alpha medium + 10% horse serum to promote myoblast 
differentiation (Jane and Dufresne 1994). On each consecutive day after initial plating, 
L6  myoblasts were stained with Giemsa and examined with an inverted microscope to 
determine their morphology and extent of myotube formation (i.e., fusion index). In
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the same experiment, cathepsin B activity was measured in cell homogenates prepared 
from day 2 through day 8  cells. Activity was assayed using the selective fluorometric 
substrate Z-phe-arg-NHMec, and the cathepsin B selective inhibitor, CA074 (Fig. 10). 
During differentiation of L6 S myoblasts, cathepsin B activity followed a “down-up” 
pattern such that activity decreased when presumptive cells aligned and formed linear 
arrays (day 4), then increased as aligned, postmitotic myoblasts fused to form 
multinucleated myotubes (days 5-7). A similar “down-up” pattern of expression was 
observed during differentiation of C2C12 mouse myoblasts plated in alpha MEM + 
10% HS (Fig.l 1). Levels of cathepsin B activity were high in presumptive myoblasts 
(day 2), decreased as these cells exited the cell cycle and formed linear arrays (day 3), 
then increased in a fusion-related manner (days 4-8). Reducing the initial 
concentration of cells plated protracted the differentiation process, but did not affect 
the general pattern of cathepsin activity. The “up-down” pattern was also not affected 
by increasing the initial concentration of cells, a procedure that shortened the 
differentiation process.
These observations, and those made by others in the field (reviewed in the 
Introduction), provided the basis for the following research hypothesis:
The regulated expression of cathepsin B plays a necessary role in the 
differentiation of mononticleated myoblasts into multinucleated myotubes.
Two experimental predictions were formulated to test this hypothesis in vitro.
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Figure 10
Levels of Cathepsin B Activity in Intracellular Fractions of L6 Cells during 
Growth and Differentiation
L6  myoblasts were seeded at 3 x lO3 cells per 100 mm dish and grown in 10% horse 
serum-supplemented medium. Each day after plating a representative plate was used to 
fix and stain cells. Fusion index (closed circles) was determined according to the method 
of Morris and Cole (1972). Starting at day 2, cells were collected every 24 hours and used 
to measure cathepsin B activity (hatched bars) using the selective substrate Z-phe-arg- 
NHMec and the cathepsin B selective inhibitor CA074. Cathepsin B activity is expressed 
as pEnzyme Units/mg protein where one Unit is defined as the amount o f protease that 
liberates 1 nmol of aminomethylcoumarin/min. Each value represents the mean of at least 
3  measurements (N=3) with error bar denoting standard error. Three successive stages of 
differentiation are represented: i) division of presumptive myoblasts (days 2-3), ii) 
alignment and adherence of postmitotic myoblasts (day 4), and iii) fusion of noncycling, 
postmitotic myoblasts to form myotubes (days 5-7). The differences in activities between 
successive stages are statistically significant (p < 0 .0 0 1 ).
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Levels of Cathepsin B Activity in Intracellular Fractions of C2C12 Cells during
Growth and Differentiation
C2C12 myoblasts were seeded at 3 x 105 cells per 100 mm dish and grown in 10% horse 
serum-supplemented medium. Each day after plating a representative plate was used to 
fix and stain cells. Fusion index (closed circles) was determined according to the method 
of Morris and Cole (1972). Starting at day 2, cells were collected every 24 hours and used 
to measure cathepsin B activity (hatched bars) using the selective substrate Z-phe-arg- 
NHMec and the cathepsin B selective inhibitor CA074. Cathepsin B activity is expressed 
as pEnzyme Units/mg protein where one Unit is defined as the amount of protease that 
liberates 1 nmol of aminomethylcoumarin/min. Each value represents the mean of at least 
3 measurements (N=3) with error bar denoting standard error. Three successive stages of 
differentiation are represented: i) division of presumptive myoblasts (day 2), ii) alignment 
and adherence of postmitotic myoblasts (days 3-4), and iii) fusion of noncycling, post­
mitotic myoblasts to form myotubes (days 5-8). The differences in activities between 
successive stages are statistically significant (p < 0.02).
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Prediction I: If the regulated expression of cathepsin B plays a necessary role in
myogenesis then alterations in the myogenic phenotype (e.g.. 
ability to form myotubes) should affect cathepsin B expression. 
Prediction II: If the regulated expression of cathepsin B plays a necessary role in
myogenesis then alterations in the expression of cathepsin B 
should affect the fusion ability o f myoblasts.
In prediction I studies, normal differentiating L6-S rat myoblasts were compared 
to: 1) a fusion-deficient variant of L6-S myoblasts (L6D3) that constituitively 
expresses high levels of cathepsin B, and 2) LM mouse fibroblasts. In prediction II 
studies, normal differentiating C2C12 mouse myoblasts were compared to: 1) a 
cathepsin B gene-trapped variant of C2C12 myoblasts (RT-27) that expresses reduced 
levels of cathepsin B as compared to C2C12, and 2) control gene-trapped variant of 
C2C12 that is trapped in a gene allele other than cathepsin B
The experimental approach to both predictions involved cell-free and whole cell 
analyses and made use of biochemical, immunological, immunocytochemical and 
molecular genetic techniques.
3.2 The Prediction I Studies
3.2.A The “Down-Up” Pattern of Cathepsin B Activity is not Observed in
Extracellular Fractions of Differentiating L6 Cells, or in Intracellular 
Fractions of Fusion-Deficient L6D3 Myoblasts or LM Fibroblasts.
The preliminary studies indicated that the differentiation of myoblasts 
was accompanied by an “down-up” pattern of cathepsin B activity within the cells.
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This result raised several questions. First, since proteases are known to interact in vivo, 
did other proteases demonstrate a similar pattern? Second, since proteases can be 
targeted to the external environment, could a similar pattern be observed in the 
medium of differentiating cells? Third, since the pattern of cathepsin B activity is 
closely linked to myotube formation, is the pattern maintained in myoblast variants 
incapable of forming myotubes? Fourth, since the pattern of cathepsin B activity 
suggests a more specific role in myoblast differentiation, is the pattern restricted to 
myoblasts?
To provide some answers to the first two questions, cathepsin B activity was 
measured in intracellular (i.e., cells) and extracellular (i.e., medium) fractions prepared 
from differentiating L6S myoblasts in culture. The activities in these fractions were 
compared to those obtained for cathepsin L-type, a related cysteine protease, and for 
cathepsin D, an aspartyl protease implicated in the processing of cathepsin B. The 
results of these analyses are presented in Figure 12. During differentiation of L6S 
myoblasts, intracellular levels of each protease activity demonstrated a similar fusion- 
related “down-up” pattern (Fig. 12A). This pattern was not observed in extracellular 
fractions (Fig. 12B). Moreover, at each time point, protease activities in extracellular 
fractions were consistently lower than activities in intracellular fractions.
To provide some answers to questions 3) and 4), the protease activities observed 
during differentiation L6 myoblasts were compared to those obtained during growth of 
L6D3 (Fig. 13), a variant of L6 incapable of forming myotubes, and during growth of 
LM (Fig. 14), an immortal, muscle fibroblast cell line. In short, the “down-up” pattern 
of protease expression was not observed in intracellular fractions o f fusion-deficient
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Figure 12
Levels of Cathepsins B, L-type and D Activities in Intracellular and 
Extracellular Fractions of L6S Myoblasts
L6 myoblasts were seeded at 5 x 105 cells per 100 mm dish and grown in 10% horse 
serum-supplemented medium. For each day beginning with day 2, the medium was 
removed from cells and replaced with fresh serum-free media. Cells were then incubated 
at 37°C for an additional 24 hours after which fusion index (closed circles), the percent 
ratio of number of nuclei in myotubes to total number of nuclei was determined by the 
method of Morris and Cole (1972). For each day beginning with day 3, cells and their 
medium were collected and used to prepare intracellular and extracellular fractions, 
respectively (Methods: 2.7). Cathepsin B activity was measured in intracellular (A) and 
extracellular pepsin/acid activated extracellular (B) fractions using the substrates Z-arg- 
arg-NHMec (solid bars) and Z-phe-arg-NFtMec (stripped bars) substrates. Cathepsin 
L-type activity was measured in intracellular (A) and extracellular pepsin/acid activated 
extracellular (B) fractions using the substrate Z-phe-arg-NHMec (open bars) and the 
cathepsin B selective inhibitor, CA074. Cathepsins B and L-type activities are expressed 
as pEnzyme Units/mg protein where one Unit is defined as the amount of protease that 
liberates 1 nmol of aminomethylcoumarin/min. Intracellular fractions (A) were also 
measured for cathepsin D activity using Hemoglobin as substrate (hatched bars) where, 
one enzyme unit is defined as that amount of enzyme required to hydrolyze hemoglobin 
at an initial rate which produces 1 pmole of acid soluble free tyrosine per minute. 
Cathepsin D activity represents total activity minus pepstatin insensitive activity. Each 
value represents the mean of at least 3 measurements (N=3) with error bar denoting 
standard error. For each of cathepsins B, L-type and D activities the difference in 
activities between consecutive days is statistically significant (p < 0 .01).
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Levels of Cathepsins B, L-type and D Activities in Intracellular and 
Extracellular Fractions of L6D3 Myoblasts
L6D3 myoblasts were seeded at 5 x 105 cells per 100 mm dish and grown in 10% horse 
serum-supplemented medium. For each day beginning on day 2, the medium was 
removed form cells and replaced with fresh serum-free medium. For each day beginning 
with day 3, cells were then incubated at 37°C for an additional 24 hours after cell counts 
(closed circles) were determined. For each day beginning with day 3, cells and their 
medium were collected and used to prepare intracellular and extracellular fractions, 
respectively (Methods: 2.7). Cathepsin B activity was measured in intracellular (A) and 
extracellular pepsin/acid activated extracellular (B) fractions using the substrates Z-arg- 
arg-NHMec (solid bars) and Z-phe-arg-NHMec (stripped bars) substrates. Cathepsin 
L-type activity was measured in intracellular (A) and extracellular pepsin/acid activated 
extracellular (B) fractions using the substrate Z-Phe-Arg-NHMec (open bars) and the 
cathepsin B selective inhibitor, CA074. Cathepsins B and L-type activities are expressed 
as pEnzyme Units/mg protein where one Unit is defined as the amount of protease that 
liberates 1 nmol of aminomethylcoumarin/min. Intracellular fractions (A) were also 
measured for cathepsin D activity using Hemoglobin (hatched bars) as substrate where, 
one enzyme unit is defined as that amount of enzyme required to hydrolyze hemoglobin 
at an initial rate which produces 1 pinole of acid soluble free tyrosine per minute. 
Cathepsin D activity represents total activity minus pepstatin insensitive activity. Each 
value represents the mean of at least 3 measurements (N=3) with error bar denoting 
standard error.
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L6D3 rat myoblasts (Fig. 13 A) or of LM mouse fibroblasts (Fig. 14A). For these cell 
lines, activities increased as the number of cells increased. Levels of cathepsin B and 
L-type activities were generally lower in extracellular fractions, but appeared to 
demonstrate similar cell number-related increases (Fig. 13B & Fig. 14B). It should be 
pointed out that detection of cathepsin B and L-type activities in fractions prepared 
from the medium of each cell line required acid/pepsin activation, while detection of 
the same activities in fractions prepared from cells did not. This is consistent with the 
secretion of proforms of the two cysteine proteases.
3.2.B During Myoblast Differentiation, the Apparent Molecular Masses of 
Cathepsins B, L-type and D Activities are Conserved. To confirm the 
results obtained in crude homogenates and to examine molecular mass-enzyme 
activity associations, intracellular and extracellular samples prepared from L6S, L6D3 
and LM growing in culture were fractionated on a FPLC driven Superose 12 HR 10/30 
column. Column fractions were collected and assayed for cathepsins B and L-type 
activities in the presence and absence of the cathepsin B selective inhibitor, CA074 
(Towatari et al. 1991), and for cathepsin D in the presence and absence of the aspartyl 
protease inhibitor, pepstatin (Turk et al. 1984). Assays were performed on day 2, day 
3 and day 5 samples plus and minus acid/activation treatment. Representative profiles 
for presumptive (day 2), postmitotic (day 3) and fused (day 5) stages of differentiating 
L6S myoblasts, and for day 5, nonfusing L6D3 cells are presented in Figure ISA, 15B, 
15C and 15D, respectively. All of the enzyme activity-molecular mass data obtained 
from such profiles is summarized in Table 3
Cathepsin B and cathepsin L-type activities in intracellular fractions o f presumptive
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Figure 14
Levels of Cathepsins B, L-type and D Activities in Intracellular and 
Extracellular Fractions of LM Fibroblasts
LM fibroblasts were seeded at 5 x 105 cells per 100 mm dish and grown in 10% horse 
serum-supplemented medium. For each day beginning on day 2, the medium was 
removed from cells and replaced with fresh serum-free medium. Cells were then 
incubated at 37°C for an additional 24 hours after cell counts (closed circles) were 
determined. For each day beginning with day 3, cells and their medium were collected 
and used to prepare intracellular and extracellular fractions, respectively (Methods: 2.7). 
Cathepsins B activity was measured in intracellular (A) and extracellular pepsin/acid 
activated extracellular (B) fractions using the substrates Z-arg-arg-NHMec (solid bars) 
and Z-phe-arg-NHMec (stripped bars) substrates. Cathepsin L-type activity was 
measured in intracellular (A) and extracellular pepsin/acid activated extracellular (B) 
fractions using the substrate Z-phe-arg-NHMec (open bars) and the cathepsin B selective 
inhibitor, CA074. Cathepsins B and L-type activities are expressed as pEnzyme 
Units/mg protein where one Unit is defined as the amount of protease that liberates 1 
nmol of aminomethylcoumarin/min. Intracellular fractions (A) were also measured for 
cathepsin D activity using Hemoglobin as substrate (hatched bars) where, one enzyme 
unit is defined as that amount of enzyme required to hydrolyze hemoglobin at an initial 
rate which produces 1 pmole of acid soluble free tyrosine per minute. Cathepsin D 
activity represents total activity minus pepstatin insensitive activity. Each value 
represents the mean of at least 3 measurements (N=3) with error bar denoting standard 
error.
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(day 2), post-mitotic (day 3) and fused (day 5) L6 myoblasts consistently eluted as 
single peaks corresponding to an apparent molecular mass of 31 kDa (Fig. 15 A, B, C, 
Table 3). A similar cathepsin B/Cathepsin L-type activity-31 kDa molecular mass 
association was observed during growth of nonfusing L6D3 myoblasts (Figure 15D, 
Table 3), and of LM fibroblasts (Table 3). Cathepsin D activity in intracellular 
fractions prepared from day 2, day 3 and day 5 myoblasts eluted at a peak position 
corresponding to an apparent molecular mass of 34 kDa (Fig. 15 A, B, C, Table 3). A 
second peak of cathepsin D activity, corresponding to a molecular mass of 48 kDa, 
was observed in day 5 (fused) L6S myoblasts (Fig. 15C, Table 3). This 48 kDa peak of 
cathepsin D activity was the predominant peak observed during growth of nonfusing 
L6D3 myoblasts (Fig. 15D, Table 3) and of LM fibroblasts (Table 3).
The levels and molecular mass positions of cathepsin activities in intracellular 
fractions were not affected by acid/pepsin treatment. In contrast, acid/pepsin treatment 
was required to detect any cathepsin B and L-type activities in extracellular fractions 
of all cell lines. The low levels of activatable cathepsin B and L-type activities 
detected in extracellular fractions of day 2, day 3 and day 5 L6S myoblasts eluted at 
single peak positions corresponding to molecular masses of 45 kDa for cathepsin B 
activity, and 40 kDa for cathepsin L-type activity (Table 3). A single 45 kDa peak of 
cathepsin B activity was also observed during growth of nonfusing L6D3 myoblasts 
and LM fibroblasts. However, two peaks of cathepsin L-type activity were detected in 
the medium of these cell lines, one at 40 kDa (days 2/3) and the other at 31 kDa (day 
5) Table 3).
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Figure 15
FPLC Separated Intracellular Cathepsins B, L-type and D Activities 
In L6S and L6D3 Myoblast Populations
Clarified homogenates were prepared from L6S myoblasts collected on day 2 (A) 
representing presumptive growth, day 3 (B) representing postmitotic myoblasts, and day 
5 (C) representing fused myoblasts. Homogenates were also prepared from L6D3 
myoblasts collected at day 5 (D) representing cells at late exponential growth. Two 
hundred ug of each homogenate was applied to, and eluted in 500 ul fractions from a 
Superose HR 10/30 FPLC column at a flow rate of 0.5 ml/min. Cathepsins B (solid 
circle) and L-type (solid triangle) activities were measured in each fraction using the 
substrate Z-phe-arg-NHMec in the presence and absence of the cathepsin B selective 
inhibitor, CA074. Cathepsins B and L-type activities are expressed as pEnzyme Units/mg 
protein where one Unit is defined as that amount of protease liberating 1 nmol of 
aminomethylcoumarin/min. Cathepsin D activity (open circle) was measured using 
hemoglobin as a substrate where, one enzyme unit is defined as that amount of enzyme 
required to hydrolyze hemoglobin at an initial rate which produces 1 mmole of acid 
soluble free tyrosine per minute. Cathepsin D activity represents total activity minus 
pepstatin insensitive activity.
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Table 3. A pparent Molecular Mass of Lysosomal Protease Activity
Fraction a Cathepsinb
Enzyme Activity Molecular Mass (kDa)c
Days 2/3 d D ay 5 rf
L6 intracellular B 31 31
L-type 31 31
D 34 48,34
L6D3 intracellular B 31 31
L-type 31 31
D 48 48
LM intracellular B 31 31
L-type 31 31
D 48 48
L6 extracellular B 45 45
L-type 40 40
L6D3 extracellular B 45 45
L-type 40 31
LM extracellular B 45 45
L-type 40 31
aL6S, L6D3 and LM fractions were prepared from cells maintained in alpha-MEM 
supplemented with 10% horse serum. For both cell and concentrated medium fractions, 
200 ug of protein was applied to an FPLC HR-10/30 column and eluted as described in
Methods: 2.9.
* Eluted intracellular and extracellular fractions were measured for cathepsin B, L-type 
and D activities according to Methods: 2.9.
c Enzyme activity molecular mass (kDa) refers to the molecular mass o f the peak 
protease activity for each fraction examined.
41 For L6S myoblasts, days 2 and 3 reflects early exponential growth and aligned/adhered 
postmitotic myoblasts respectively, while day 5 reflects fusing myoblasts. For L6D3 
myoblasts and LM fibroblasts days 2/3 reflects early exponential growth and day 5 
reflects late exponential growth
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3.2.C During Differentiation L6S Myoblasts, Levels of Cathepsin B Protein 
follow a “Down-Up” Pattern. This Pattern is not Observed in 
Nonfusing L6D3 Myoblasts. As noted previously, most comparisons of 
cathepsin B activity expressed in differentiating myoblasts have focused on 
comparisons between nonfused and fused populations of cells (Kirschke et a!., 1983; 
Ebisiu et al., 1994). By their design, these studies would not have detected a “down- 
up” pattern o f cathepsin B activity. A similar limitation extends to most studies of 
protein levels. In view of this, I next examined levels of cathepsin B protein in 
fractions prepared each day (i.e., 2 through 5) during the differentiation of L6S 
myoblasts and during growth of nonfusing L6D3 myoblasts using immunoblot 
analysis (Fig. 16).
The cathepsin B staining pattern for the purified cathepsin B standard demonstrated 
a 31 kDa single chain form and a heavy chain doublet (25 kDa & 26 kDa) of the fully 
processed double chain form (Moin et al. 1992). The 5 kDa light chain form was not 
visible on this gel. The staining pattern for L6S (Fig. 16 A) is consistent with a “down- 
up” pattern of cathepsin B protein. Specifically, levels of cathepsin B protein 
decreased from day 3 to day 4 as myoblasts aligned and formed linear arrays, then 
increased from day 4 to day 5 as aligned myoblasts fused to form multinucleated 
myotubes. This pattern is temporally related to the pattern of cathepsin B activity 
reported in section 3.2.A. A “down-up” pattern of cathepsin B protein was not 
observed during growth of nonfusing L6D3 (Fig. 16 B). For each cell line, bands 
migrated to an apparent molecular mass of 31 kDa, corresponding to the mature active 
single chain form of human liver cathepsin B. In addition, at maximum fusion of L6S
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F ig u re  16
Immunoblot Analyses of Cathepsin B in L6S and L6D3 Cell Homogenates
L6S and L6D3 cells were seeded at 3 x 105 cells per 100mm tissue culture plate in 10% 
horse serum supplemented medium. Starting on day 2 of growth, cells were collected, 
homogenized and run using SDS-PAGE at 80 ng per sample (methods 2.10). Immunoblot 
analysis of cathepsin B was performed on intracellular homogenates of L6S (A) and 
L6D3 (B) using a rabbit anti-human liver cathepsin B monospecific antibody and 
enhanced chemiluminescence (Methods: 2.10). In A, lanes 1 and 2 represent homogenate 
from L6S presumptive myoblasts (days 2-3), lane 3 is homogenate from post-mitotic 
myoblasts (day 4) and lane 4 is homogenate from fused myoblasts (day 5). In B, lanes 1-4 
represent L6D3 intracellular homogenates from days 2-5 of growth respectively. Purified 
cathepsin B migrated at positions corresponding to 31 and 25/26 kDa. Standards were 
used to determine the molecular mass range indicated to the left of each blot.
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(i.e.. day 5) and throughout growth of L6D3 (i.e., days 2-5), a second band 
consistently appeared. The position of this band corresponded to a molecular mass of 
25-26 kDa. This molecular mass is consistent with the heavy chain doublet of the 
fully processed form of cathepsin B.
Immunoblot analysis was also performed on extracellular fractions of differentiating 
L6 and nonfusing L6D3 myoblasts. Since medium had to be concentrated to detect 
any protein, results from only two points, day 2 and day 5, were obtained (Fig. 17). 
Both L6S and L6D3 demonstrated a predominant band of cathepsin B at a position 
corresponding to a molecular mass of 45 kDa (Fig. 17 A). The staining pattern for 
cathepsin L was also examined in this particular study (Fig. 17 B). Both L6S and 
L6D3 demonstrated a predominant band of cathepsin L at a position corresponding to 
a molecular mass of 40 kDa. The immunoblot analysis results are consistent with the 
secretion of proforms of cathepsin B and L into the medium of cells, and confirm the 
results obtained using FPLC analysis (Table 3).
3.2.D During Differentiation of L6S Myoblasts, Cathepsin B mRNA Levels
are Induced. The next logical step in these analyses was to determine if 
the differentiation-related patterns of cathepsin B protein and activity were due to 
alterations in the level of cathepsin B mRNA transcription. This was done by 
Northern blot analysis of the total cellular RNA isolated from L6S and L6D3 
myoblasts using a DIG-labeled, cathepsin B mRNA probe specific to exons 7-11.
The RNA was extracted from four distinct populations of L6S myoblasts: dividing, 
presumptive cells (day 2), aligned postmitotic cells (day 3), fusing cells (day 4), and 
maximally fused cells (day 5) (Fig. 18, lanes 1-4). Hybridization of L6S RNA from
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Figure 17
Immunoblot Analyses of Cathepsins B and L Secreted From 
L6S and L6D3 Myoblasts
L6S and L6D3 cells were seeded at 3 x 105 cells per 100mm tissue culture plate in 10% 
horse serum-supplemented medium. Starting at day 2 of growth, medium from cells were 
collected, concentrated and run using SDS-PAGE at 80 ng per sample (methods 2.10). 
Immunoblot analyses of cathepsins B (A) and cathepsin L (B) were performed on 
concentrated media samples using a rabbit anti-human liver cathepsin B monospecific 
antibody and mouse anti-human liver cathepsin L antibody respectively (Methods 2.10). 
In both A and B, lanes 1 and 2 represent extracellular concentrated media from 
presumptive and fused L6S cells respectively while lanes 3 and 4 represent extracellular 
concentrated media from L6D3 cells at early and late growth respectively. Standards 
were used to determine the molecular mass range indicated to the left o f each blot.
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each cell population gave strong bands at positions corresponding to 2.2 kb. The signal 
intensity of these bands increased as postmitotic cells fused to form myotubes (i.e., 
days 3-4). Two other bands of lower signal intensity also consistently appeared, one at
4.0 kb and the other at 1.2 kb. Washing of the blots using highly stringent conditions 
did not affect the banding patterns.
Hybridization of the cathepsin B probe to RNA extracted from nonfusing L6D3 
myoblasts also gave strong bands at the 2.2 kb position (Fig. 18, lanes 5-9). However, 
unlike differentiating L6S myoblasts, there was no apparent alteration in band 
intensities during growth. L6D3 myoblasts also demonstrated low intensity bands at
4.0 kb and 1.2 kb positions.
3.2.E Levels of Muscle Specific Creatine Phosphokinase (CPK)
Enzyme Activity is Altered in Nonfusing L6D3 Myoblasts. A 
fusion-related increase in creatine phosphokinase (CPK) activity has been used since 
the 1970s as a muscle-specific biochemical marker for myoblast differentiation in 
culture (Dufresne et al. 1976). Logically, this pattern, like that of cathepsin B, should 
be altered in myoblasts incapable of forming myotubes. Creatine phosphokinase 
activity was measured in fractions prepared from day 2 and day 5 populations of L6S 
and L6D3 myoblasts, and of LM fibroblasts (Table 4). In short, the 3-fold increase in 
CPK activity from day 2 (i.e., dividing) to day 5 (i.e., fusing) populations of L6S was 
not observed in L6D3 myoblasts or LM fibroblasts. In L6D3 and LM, levels of CPK 
activity were similar in day 2 and day 5 populations. The levels o f two nonspecific, 
ubiquitous enzymes, lactate dehydrogenase (LDH) and myokinase (MK) did not 
increase from day 2 to day 5 for any cell line tested (Table 4).
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Figure 18
Levels of Cathepsin B mRNA during Differentiation of L6S 
and during Growth of L6D3 Myoblasts
L6S and L6D3 cells were seeded at 3 x 105 cells per 100 mm tissue culture plate in 10% 
horse serum supplemented medium. Starting on day 2 of growth, total RNA was isolated 
from cells using TRIsol and isopropanol precipitation according to methods (Methods: 
2.11). For each sample, 20 nanograms of total RNA was run on a 1% agarose gel and 
transferred to a nitrocellulose membrane (see methods section 2.11 B,C). The blot was 
hybridized to a DIG-labeled RNA probe specific to exons 7-11 of cathepsin B and the 
hybridized probe was detected using anti-Digoxygenin-AP conjugate and CDP-star 
according to methods (section 2.11 D,E). Lanes 1-4 represent days 2-5 of L6S myoblast 
growth and differentiation, and lanes 5-9 days 1 -5 of L6D3 myoblast growth. Equal 
loading of sample RNA was verified by examining levels of 18s and 5s RNAs.






















R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
93
Table 4. Sum m ary of Muscle and Non-Muscle Specific Enzyme Activities 
of L6S, L6D3 and LM
Enzyme A ctivity*







L6S Myoblasts 2 0.58 +/- 0.03 112.0 +/- 4.6 46.6 +/- 2.0
5 1.75+/- 0.20 138.9+/-6.3 43.0 +/- 1.1
L6D3 Myoblasts 2 0.83 +/- 0.60 227.1 +/- 9.9 36.6 +/- 1.2
5 0.81 +/- 0.33 237.3 +/- 5.2 35.4 +/-1.2
LM Fibroblasts 2 0.05 +/- 0.02 48.3 +/- 0.4 40.0 +/- 0.4
5 0.25 +/- 0.08 31.0+/-1.2 34.5 +/- 4.8
a L6S, L6D3 and LM homogenates were prepared from cells maintained in a-MEM 
supplemented with 10% horse serum and assayed for creatine phosphokinase (CPK),
lactate dehydrogenase (LDH) and myokinase (MK) enzyme activities (Methods: 2.8).
AActivities are expressed as micromoles product formed per min per mg protein and the 
values represent mean averaged activities where n =3.
cFor each cell line, day 2 reflects dividing presumptive myoblasts and day 5 reflects 
fusing myoblasts.
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3.2.F A Redistribution of Cathepsin B Occurs during Differentiation of L6S 
bu t not during Growth of L6D3. Procathepsin B is synthesized on 
polysomes o f the rough endoplasmic reticulum close to the nucleus (see Fig. 9). To 
play a role in myoblast-myobiast fusion, it is reasonable to predict that cathepsin B 
should be redistributed toward the membrane of fusing cells. Immunocytochemistry 
and confocal image analysis were used to examine this prediction. The intracellular 
distribution of cathepsin B was delineated using an anti-human liver cathepsin B 
primary antibody and a secondary antibody conjugated to Texas-Red. Intracellular 
staining of cathepsin B in presumptive, postmitotic and fused populations of L6S rat 
myoblasts and of non-fusing L6D3 rat myoblasts and LM mouse fibroblasts are 
presented in Figure 19. In dividing, presumptive L6S myoblasts (Fig. 19 A), the 
cathepsin B staining was punctate and concentrated in the perinuclear region. 
However, when these myoblasts became aligned and began forming myotubes, 
cathepsin B staining was distributed throughout the cytoplasm (Fig. 19 B & C). The 
staining in the largest myotubes appeared to be diffuse and less intense than the 
staining patterns at early stages (Fig. 19 C). This redistribution pattern was not 
observed during growth of nonfusing L6D3 myoblasts (Fig. 19 D & E) or during 
growth of LM fibroblasts. Only one example image of cathepsin B staining in LM 
fibroblasts is presented in Figure 19 (i.e., Fig. 19 F).
3.2.G The Cell-Penetrating, Cathepsin B Selective Inhibitor, CA074M©
Blocks the Formation of Myotubes during My ©genesis. Cathepsin B 
selective inhibitors were used to determine the functional significance of the 
differentiation-related pattern of cathepsin B expression that occurs during
with perm ission  o f  the copyright owner. Further reproduction prohibited without perm ission.
95
Figure 19
Immunocytochemical Localization of Cathepsin B within 
L6S, L6D3 and LM Cells
L6S and L6D3 myoblasts as well as LM fibroblasts were seeded at 8 x Iff to 5 x 104 
cells per well, of a 24 well tissue culture plate and grown in 10 % horse serum- 
supplemented medium. At the desired state of differentiation or confluency, cells were 
fixed and then stained for cathepsin B using rabbit anti-human liver cathepsin B IgG as 
primary antibody and Texas Red-conjugated affinity-purified donkey anti-rabbit IgG as a 
secondary antibody (Methods 2.12). In L6S presumptive myoblasts (A), the cathepsin B 
staining (arrows) was punctate and concentrated in the perinuclear region. In L6S 
postmitotic myoblasts (B) and (C), there is a redistribution of cathepsin B towards the 
plasma membrane. In L6S fused myoblasts, i.e. myotubes (C) cathepsin B staining 
remained peripheral but more diffuse than that of either presumptive or postmitotic L6S 
myoblasts. In contrast, both nonfusing L6D3 myoblasts (D,E) and LM fibroblasts (F) 
demonstrated punctuate (i.e. visicular) cathepsin B staining at the perinuclear region of 
the cell during all stages of growth.
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differentiation of L6S rat myoblasts in culture. The cathepsin B selective, penetrating 
inhibitor CA074Me was added to L6S myoblast cultures every 48 hours to determine 
what effect these inhibitors had on cell fusion. These results were compared to those 
obtained using the nonpenetrating form of the cathepsin B selective inhibitor, CA074, 
and the general cysteine protease inhibitor, E-64 (Figure 20). Compared to nontreated 
(Fig. 20 A) and DMSO treated (Fig. 20 B) controls, fusion was inhibited in L6S cells 
exposed to 5 uM (Fig. 20 C) and 10 uM (Fig. 20 D) CA074Me. The greater effect at 
10 uM suggests that inhibition is dose-dependent. No inhibition was observed in L6S 
myoblasts exposed to 10 uM concentrations of nonpenetrating CA074 (Fig. 20 E) or 
E-64 (Fig. 20 F).
3,3 The Prediction II Studies
The analyses of cathepsin B expression and localization provide indirect support 
for the role of cathepsin B during myoblast differentiation. This support is 
strengthened by the apparent redistribution of cathepsin B toward the membrane of 
fusing myoblasts, and the inhibition of myotube formation by a penetrating, selective 
inhibitor of cathepsin B. To further test the hypothesis and to provide more direct 
evidence for a functional role for cathepsin B during myogenesis, I examined the 
second prediction outlined at the beginning of this section. If the regulated 
expression of cathepsin B plays a necessary role in myogenesis, then alterations in 
the expression of cathepsin B should affect the fusion ability of myoblasts
Prediction II was tested using the differentiating, C2C12 mouse myoblast cell 
culture system. This system allowed the comparison of normal differentiating C2C12
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Figure 20
Effect of Cysteine Protease Selective Inhibitors on L6S Myoblast Differentiation
L6S cells were seeded at 1 x 105 cells per 60 mm dish in 10% horse serum-supplemented 
media. After 24 hours of growth (day 1), the medium was replaced with fresh 10% horse 
serum-supplemented medium containing 5 or 10 uM of protease inhibitor. Every 48 
hours beginning on day 2, the medium was replaced with fresh inhibitor containing 
medium and on day 6, the cells were fixed with ethanol and stained with Giemsa. Panels 
A and B represent control and DMSO treated cells, respectively. Panels C and D 
represent cells exposed to 5 and 10 pM of the membrane permeable, cathepsin B 
selective inhibitor CA074Me, respectively. Panel E represents cells exposed to 10 pM of 
the non-permeable, cathepsin B selective inhibitor CA074, and panel F represents cells 
exposed to 10 uM of the non-permeable, cysteine protease selective inhibitor E-64. 
Fusion Index values were: i) >80% for non-treated, DMSO-, CA074-, and E-64-treated 
cells, and ii) <40% and <5% for 5 and 10 pM CA074Me-treated cells, respectively.
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mouse myoblasts with a cathepsin B gene-trapped variant of C2C12 that expresses 
reduced levels of cathepsin B protein due to insertional mutagenesis in the 5’ 
regulatory region of one of the two cathepsin B gene alleles (Fig. 21). A third C2C12 
variant, RT-11, trapped in a gene other than cathepsin B provided a control for the 
gene-trapping procedure.
3.3. A Serum Affects the Growth of Cathepsin B Gene-Trapped RT-27
Myoblasts. The study of myoblast differentiation in cell culture 
routinely involves a transfer from medium supplemented with 10% fetal calf serum 
(i.e., nondifferentiating medium) to medium supplemented with horse serum (i.e., 
differentiating medium) (Gogos et al. 1996). It has been my experience that both the 
transfer to and the concentration of horse serum can affect the growth, and ultimately 
the differentiation phenotype of the cells. To minimize the contribution of this 
confounding variable, I first established growth conditions that supported optimal 
growth and differentiation of the control and the cathepsin B gene-trapped C2C12 
myoblast cell lines (Fig. 22). Cells were cultured in alpha MEM medium 
supplemented with: 1) 10% horse serum (10HS), or 2) 10% fetal calf serum then 
replaced after 48 hours with medium supplemented with 2% (10FCS/2HS) or 10% 
horse serum (10FCS/10HS). For both cell lines, the increase in cell number over time 
was similar in 10HS and in 10FCS/10HS growth conditions. Compared to these levels, 
the cell number in 10FCS/2HS growth conditions was reduced by 20-30% at each time 
point after transfer to 2% horse serum; the greatest reduction was observed for 
cathepsin B gene-trapped RT-27 cells. Results for RT-11 cells, variants of C2C12 
trapped in a gene other than cathepsin B, were comparable to those for control C2C12
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Figure 21
Cathepsin B Gene-Trapping of C2C12 Mouse Myoblasts
C2C12 mouse myoblasts were trapped in one allele of the cathepsin B gene by 
insertional mutagenesis using a retroviral ROSA(3geo gene trap vector containing 
a splice acceptor 5’ to a gene encoding a fusion protein of p-gaiactosidase and 
neomycin phosphotransferase (pgeo) (Gogos et al. 1996). This vector was 
inserted into the 5’ untranslated region of one allele of the cathepsin B gene 
resulting in cathepsin B gene-trapped myoblasts (RT-27) expressing 
approximately 50% less cathepsin B protein relative to nontrapped C2C12 
myoblasts and control-trapped (i.e. trapped in a gene other than cathepsin B) 
myoblasts (RT-11).
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Figure 22
Growth of C2C12 and Cathepsin B Gene-Trapped RT-27 Myoblasts 
in Serum Containing Medium
C2C12 (A) and RT-27 (B) myoblasts were seeded in 60 mm dishes at 1 x 105 cells per 
dish. For each panel, circles represent cells plated in 10% FCS containing media 
followed by a switch to 10% HS containing media after 48 hours of growth. Boxes 
represent cells plated in 10% FCS containing media followed by a switch to 2% HS 
containing media after 48 hours of growth, and triangles represent cells plated in 
10%HS. Every 12 hours of growth, two plates of cells grown under each condition were 
counted and the values used to construct growth curves.
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cells (data not shown). In view of these results, all subsequent analyses were 
conducted in medium supplemented with 10% horse serum. Saturation densities for 
C2C12, RT-11 and RT-27 in 10HS were 8 x 10\ 8 x 104 and 11 x 104 cells/cm2, 
respectively; population doubling times were 17, 18 and 11 hours, respectively.
33.B During Differentiation of Control C2C12 and Cathepsin B Gene- 
Trapped RT-27 Myoblasts, Levels of Cathepsin B Activity follow a 
“Down-Up” Pattern 
Since levels of cathepsin B protein in cathepsin B gene-trapped non-fused and 
fused C2C12 myoblast preparations are reduced relative to control C2C12 cells 
(Gogos et al. 1996), I have examined the effect of reduced protein levels on levels of 
activity during differentiation of cathepsin B gene-trapped RT-27 myoblasts. Control 
C2C12 and cathepsin B gene-trapped RT-27 myoblasts were plated at 2 x lOVplate. 
On days 2 through 8, cell homogenates were prepared and assayed for cathepsin B 
activity using the fluorometric substrate, Z-phe-arg-NHMec, and the cathepsin B 
selective inhibitor, CA074 (Fig. 23). In both control C2C12 and cathepsin B gene- 
trapped RT-27 myoblast preparations, levels of cathepsin B activity decreased 
dramatically on day 3 (i.e., down) when presumptive myoblasts aligned, then 
increased (i.e., up) as aligned, post-mitotic myoblasts fused to form multinucleated 
myotubes. The “down-up” pattern of cathepsin B activity observed during myoblast 
differentiation is consistent with the pattern observed in differentiating L6-S rat 
myoblasts (Jane and Duffesne 1994; section 3.2.A, Fig. 10 of results), and in X-gal 
stained C2C12 myoblasts and myotubes (Gogos et al. 1996). Although both C2C12 
and RT-27 demonstrated a differentiation related “down-up” pattern of cathepsin B
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Figure 23
Levels of Cathepsins B Activity in Intracellular Fractions of 
C2C12 and RT-27 Myoblasts
C2C12 and RT-27 myoblasts were seeded at 3 x 105 cells per 100 mm dish and grown in 
10% horse serum-supplemented medium. Starting at day 2 cells were collected every 24 
hours and used to measure cathepsin B activity of C2C12 (solid bars) and RT-27 (open 
bars) using the substrate Z-phe-arg-NHMec and the cathepsin B selective inhibitor, 
CA074. Cathepsin B activity is expressed as pEnzyme Units/mg protein where one Unit 
is defined as the amount of protease that liberates 1 nmol of aminomethylcoumarin per 
minute. Three successive stages of differentiation are represented: i) division of 
presumptive myoblasts (days 2-3), ii) alignment and adherence of postmitotic myoblasts 
(days 4-5), and iii) fusion of noncycling, postmitotic myoblasts to form myotubes (days 
6-9). Each value represents the mean of at least 3 measurements (N=3) with error bar 
denoting standard error. For both C2C12 and RT-27, the differences in activities between 
successive stages are statistically significant (p < 0.02).
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activity, levels of cathepsin B activity in RT-27 were significantly lower than activity 
levels in C2C12 at each stage of differentiation.
3.3.C Levels of Cathepsins L-type Activity in Fusing Populations of 
Cathepsin B Gene-Trapped RT-27 Myoblasts are not Reduced 
Relative to Activity Levels obtained in Control C2C12 and Gene- 
Trapped RT-11 Myoblasts. Since proteases interact in vivo, it is possible
that alterations in activity levels of one protease will affect activity levels of others. In 
view of this, I examined the activity levels of two other lysosomal proteases: the 
cysteine protease, cathepsin L (Fig. 24 A), and the aspartyl protease, cathepsin D (Fig. 
24 B). Activities were measured in cell homogenates prepared from early dividing, 
presumptive (day 2) and fusing (day 7) C2C12, cathepsin B gene-trapped myoblasts 
RT-27, and control gene trapped RT-11 myoblasts. For RT-27, cathepsin L-type 
activity was greatest in day 7 homogenates; this activity was, in turn, greater than 
activities in day 7 C2C12 or RT-11 homogenates. In contrast, for C2C12 and RT-11, 
cathepsin L-type activity was greatest in day 2 homogenates; this activity was, in turn, 
greater than activities in day 2 RT-27 homogenates. Levels of cathepsin D activity 
were greatest in day 7 homogenates of each cell line, but similar at each time point 
among cell lines (Fig. 24 B).
3.3.D At each Stage of Differentiation, Cathepsin B Activity in C2C12, RT- 
11, and RT-27 Elute as a Single Peak at a Position corresponding to a 
Molecular Mass of 31 kDa. To confirm the cathepsin B results obtained
in crude homogenates and to examine molecular mass-enzyme activity associations, 
cell homogenates prepared from C2C12, RT-11 and RT-27 were fractionated on an
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Figure 24
Levels of Cathepsins L-type and D Activities in Intracellular Fractions of 
C2C12, RT-27 and RT-11 Myoblasts
C2C12, RT-27 and RT-11 myoblasts were seeded at 3 xlO5 cells per 100 mm tissue 
culture dish and collected at 2 and 7 days after plating reflecting presumptive and fusing 
stages of differentiation respectively. Intracellular fractions of C2C12 (solid bar), RT-11 
(striped bar), and RT-27 (open bar) were measured for cathepsin L-type (A) activity 
using Z-phe-arg-NHMec and the selective cathepsin B inhibitor, CA074, and for 
cathepsin D (B) activity using hemoglobin and pepstatin. Cathepsin L-type enzyme 
activity is expressed as pEnzyme Units/mg protein where one Unit is defined as that 
quantity of protease that liberates 1 nmol of aminomethylcoumarin per minute. Cathepsin 
D enzyme activity (total activity minus pepstatin insensitive activity) is expressed as 
mAnson Units per mg protein where one Unit is defined as that amount of enzyme 
required to hydrolyze hemoglobin at an initial rate which produces 1 pmole of acid 
soluble free tyrosine per minute. Each value represents the mean of at least 3 
measurements (N=3) with error bar denoting standard error.
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FPLC-driven Superose 12 HR 10/30 column. Column fractions were collected and 
measured for cathepsin B activity in the presence and absence of the cathepsin B 
selective inhibitor CA074 (Towatari et al. 1991). Representative profiles for 
presumptive (day 2), and fused (day 7) stages are presented in Figure 25 A and Figure 
25 B, respectively. Two results were consistently obtained. First, peak levels of 
cathepsin B activity in the RT-27 cathepsin B gene-trapped cells were approximately 
50% lower than those in control C2C12 and gene-trapped RT-11 cell lines. Second, a 
single peak of cathepsin B activity eluting at a position corresponding to a molecular 
mass of 31 kDa was observed for presumptive and fused myoblasts of each C2C12 
cell line analyzed. A 31 kDa peak of activity was also observed in aligned, post­
mitotic (day 4/5) myoblasts. This molecular mass is consistent with that reported for 
cathepsin B activity in differentiating L6S rat myoblasts (Jane and Dufresne 1994; 
section 3.2.B, Fig. 15 A, B, C, and Table 3) and for cathepsin B protein in C2C12 
myoblast and myotube populations (Ebisui et al. 1995).
3.3.E During Differentiation, Levels of Cathepsin B Protein in Cathepsin B 
Gene-Trapped RT-27 Myoblasts are Reduced Relative to Control 
C2C12 and Gene-Trapped RT-11 Myoblasts. Previous comparisons 
between cathepsin B gene-trapped and normal C2C12 myoblasts focused on nonfused 
and fused populations (Gogos et al. 1996). Since differentiation is a progressive 
process, I used immunoblot analysis to examine levels of cathepsin B protein in 
fractions prepared each day of differentiation of control C2C12 (Fig. 26 A), cathepsin 
B gene-trapped RT-27 (Fig. 26 B), and control gene-trapped RT-11 (Fig. 26 C) 
myoblasts. The cathepsin B staining pattern for the purified cathepsin B standard
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Figure 25
FPLC Profiles of Cathepsin B Activity in 
C2C12, RT-11 and RT-27 Cell Homogenates
Fast protein liquid chromatography (FPLC) analysis of cathepsin B activity was 
performed for cell homogenates prepared from C2C12, RT-11, and RT-27 myoblasts. 
Cells were seeded at 3 x 105 cells per 100 mm tissue culture plate and collected at 2 (A) 
and 7 (B) days after plating reflecting presumptive and fusing stages of differentiation 
respectively. Equal amounts (200 ug/protein) of each homogenate were applied to a 
sepharose 12 HR 10/30 FPLC column and eluted at a flow rate of 1 mL/min. Five 
hundred uL volumes were collected and measured for cathepsin B activity using Z-phe- 
arg-NHMec and the cathepsin B selective inhibitor, CA074. Cathepsin B activity is 
expressed as pEnzyme Units/mg protein where I Unit is defined as the quantity of 
protease that liberates 1 nmol aminomethylcoumarin/min.
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demonstrated a 31 kDa single chain heavy form and a heavy chain doublet (25 kDa &
26 kDa) o f the fully processed double chain form (Moin et al. 1992). The 5 kDa light 
chain form was not visible on this gel. The cathepsin B staining patterns for myoblast 
cell lines suggest that: 1) levels of cathepsin B protein decrease in aligned, post­
mitotic myoblasts of each cell line (i.e., day 6 for C2C12 and day 5 for RT-11 and RT-
27 due to differences in population doubling time) then increase as aligned myoblasts 
fused to form myotubes, 2) cathepsin B protein levels are lower in differentiating 
cathepsin B gene-trapped RT-27 myoblasts than in control C2C12 and RT-11 
myoblasts, and 3) the major cathepsin B form during differentiation of all cell lines 
corresponds to a molecular mass of 31 kDa. The pattern of cathepsin B protein 
staining during myoblast differentiation is consistent with the “down-up” pattern 
observed for cathepsin B activity.
3.3.F During Myotube Formation, Levels of Cathepsin L Protein in 
Cathepsin B Gene-Trapped RT-27 Myoblasts are not Reduced 
Relative to Control C2C12 Myoblasts. Cell fractions were also 
examined for cathepsin L protein (Fig. 27). The staining pattern for purified cathepsin 
L demonstrated a 26 kDa heavy chain form (Mason and Massey 1992). The 5 kDa 
light chain was not visible on this gel. There appears to be a “down-up” pattern of 
cathepsin L protein similar to that for cathepsin B during differentiation of C2C12 and 
RT-27 myoblasts. Specifically, staining patterns suggest that levels of the predominant 
26 kDa form of cathepsin L decrease (i.e., down) in aligned, post-mitotic myoblasts of 
C2C12 (Fig. 27 A) and RT-27 (Fig. 27 B) (i.e., day 6 for C2C12 and day 5 for RT-27 
due to differences in population doubling time), then increase (i.e., up) as aligned
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Figure 26
Immunoblot Analyses of Cathepsin B in 
C2C12, RT-27 and RT-11 Cell Homogenates
Each myoblast cell line was seeded at 3 x 105 cells per 100mm tissue culture plate in 
10% horse serum supplemented medium. Starting at day 2 of growth, cells were 
collected, homogenized and run using SDS-PAGE at 80 ng per sample (methods 2.10). 
Immunoblot analysis of cathepsin B was performed on intracellular homogenates of 
C2C12 (A), RT-27 (B) and RT-11 (C) using mono-specific rabbit anti-human liver 
cathepsin B antibody and enhanced chemiluminescence (Methods: 2.10). Lane 1 was 
loaded with cathepsin B purified from human liver. For C2C12 (A), lanes 2 through 5 
represent presumptive growth (days 2-5), lane 6 represents postmitotic myoblasts (day 6) 
and lanes 7-8 represent fusing myoblasts (days 7-8). For RT-27 (B) and RT-11 (C) lanes 
2-4 represent presumptive growth (days 2-4), lane 5 represents postmitotic growth (day 
5) and lanes 6-8 represent fusing myoblasts (days 6-8). Purified cathepsin B migrated at 
positions corresponding to 31 and 25/26 kDa. Standards were used to determine the 
molecular mass range indicated to the left of each blot.
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myoblasts fuse to form myotubes. Like cathepsin B, during the early stages of 
differentiation there appears to be a reduction in staining intensity of the predominant 
molecular mass form of cathepsin L (i.e., 26 kDa) in RT-27 relative to C2C12. 
However, unlike cathepsin B, once myotube formation begins, there is no apparent 
reduction in the staining intensity of this band in RT-27 relative to C2C12; in fact, 
staining appears to be more intense in RT-27 than in C2C12. This latter result is 
consistent with the differences observed between cathepsin B and cathepsin L-type 
activities in fusing populations of RT-27 and C2C12. Results for control, gene-trapped 
RT-11 cells were comparable to those for C2C12.
3.3.G Reduced Levels of Cathepsin B are Associated with Alterations in the 
Activity of the Muscle Specific Enzyme Marker, Creatine 
Phosphokinase (CPK), but not in the Activities of Two Nonspecific 
Enzymes, Lactate Dehydrogenase (LDH) and Myokinase (MK). The 
fusion-related increase in creatine phosphokinase (CPK) activity is a well-established 
muscle-specific biochemical marker for myoblast differentiation in culture (Dufresne 
et al. 1976). The potential effect of reduced levels of cathepsin B on this increase was 
examined by measuring CPK activity in cell homogenates prepared from presumptive 
(day 2) and fused (day 7) populations of each cell line (Table 5). Within each cell line, 
levels of CPK activity increased 2-3 fold from day 2 to day 7. However, among cell 
lines, absolute levels of activity were 5-6 fold lower in homogenates prepared from 
day 2 and day 7 cathepsin B gene-trapped RT-27 cells than levels in the corresponding 
homogenates prepared from C2C12 or gene-trapped RT-11 cells. In contrast, levels of 
lactate dehydrogenase (LDH) and myokinase (MK) activities did not increase from
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
117
Figure 27
Immunoblot Analyses of Cathepsin L in 
C2C12 and RT-27 Cell Homogenates
C2C12 and RT-27 myoblasts were seeded at 3 x 105 cells per 100mm tissue culture plate 
in 10% horse serum supplemented medium. Starting at day 2 of growth, cells were 
collected, homogenized and run using SDS-PAGE at 80 ng per sample (Methods: 2.10). 
Immunoblot analysis of cathepsin B was performed on intracellular homogenates of 
C2C12 (A), and RT-27 (B) myoblast homogenates using a mono-specific mouse anti­
human liver cathepsin L antibody and enhanced chemiluminescence (see methods section
2.11). For C2C12 (A), lanes 2 through 5 represent growth of presumptive myoblasts 
(days 2-5), lane 6 represents postmitotic myoblasts (day 6) and lanes 6-8 represent fusing 
myoblasts (days 7-8). For RT-27 (B), lanes 2-4 represent growth of presumptive 
myoblasts (days 2-4), lane 5 represents post-mitotic growth (day 5) and lanes 6-8 
represent fusing myoblasts (days 6-8). Purified cathepsin L migrated at a position 
corresponding to 26 kDa. Standards were used to determine the molecular mass range 
indicated to the left of each blot.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
C2C12 days after plating









RT-27 days after plating 
cat. L 2 3 4 5 6 7 8 B
21
14
divide/ slig« /  adhere /  fuse 
Myogenesis
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
119
day 2 to day 7. and were similar in the three myoblast cell lines.
3.3.H Reduced Levels of Cathepsin B are Associated with Alterations in
Myotube Physiology. The association between reduced levels of 
cathepsin B and biochemical differentiation, vis-a-vis reduced levels of CPK activity, 
prompted me to examine physiological differentiation, i.e., myoblast division and 
myotube formation, in cathepsin B gene-trapped myoblasts (Fig. 28). It is clear that 
both the extent of myotube formation over time (Fig. 28 A: percent fusion), and the 
size of each myotube (compare Fig. 28 C and 28 E: the number of nuclei within a 
myotube) were dramatically reduced in RT-27 cathepsin B gene-trapped relative to 
C2C12 control myoblasts. These differences became apparent after day 5 when 
aligned, post-mitotic cells began fusing (Fig. 28 A). Both the onset of fusion and the 
appearance of myoblasts prior to day 5 were similar (compare Fig. 28 B & D). Results 
for control, gene-trapped RT-11 cells were comparable to those for C2C12.
3.3.1 The Localization of Cathepsin B during Differentiation of Cathepsin 
B Gene-Trapped RT-27 Myoblasts is Similar to that of Control 
C2C12. Immunocytochemistry and confocal image analysis were used to 
examine the distribution of cathepsin B during differentiation and to determine the 
effect of cathepsin B gene trapping on this distribution (Fig. 29). In short, the staining 
patterns were qualitatively similar in control C2C12, and cathepsin B gene-trapped 
RT-27 myoblast cell lines. In each case, cycling presumptive myoblasts demonstrated 
punctate cathepsin B staining with perinuclear localization (Fig. 29 A, C). The 
staining became redistributed throughout the cytoplasm as myoblasts aligned and 
fused (Fig. 29 B, D). This general pattern of redistribution was also observed in
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Table 5. Summary of Muscle and Non-Muscle Specific Enzyme Activities 









C2C12 2 0.87 +/- 0.07 110.5+/- 3.8 44.8 +/- 1.1
7 3.75 +/-1.40 161.2+/- 0.9 41.4+/-0.8
RT11 2 0.89 +/- 0.37 151.3+/-30.3 45.7 +/- 0.4
7 2.32 +/- 0.33 221.5+/- 0.7 40.5 +/- 1.4
RT27 2 0.15+/-0.05 74.4 +/- 5.4 39.4 +/- 3.1
7 0.51 +/- 0.39 161.2+/-19.5 41.8+/-3.3
a C2C12, RT-11 and RT-27 homogenates were prepared from cells maintained in 
oc-MEM supplemented with 10% horse serum and assayed for creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH) and myokinase (MK) enzyme activities (Methods:
»2’8>: . .Activities are expressed as micromoles product formed per min per mg protein and the 
values represent mean averaged activities where n =3. 
c For each cell line, day 2 reflects dividing presumptive myoblasts and day 7 reflects 
fusing myoblasts.
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Figure 28
Myotube Formation in and Morphology of Differentiating C2C12 and Cathepsin B
Gene-Trapped RT-27 Myoblasts
C2C12 (circles) and RT-27 (boxes) myoblasts were plated in medium containing 10% 
HS and allowed to differentiate. Each day, cells were fixed, stained with Giemsa and 
used to determine percent fusion (A) according to methods (Methods: 2.6). Photographs 
of cells at two stages of differentiation are included: early, presumptive (day 3) (B: 
C2C12; D: RT-27), and late, fused (day 9) (C: C2C12; E: RT-27) myoblasts. The range 
number of nuclei per myotube was 3-60 for C2C12 and RT-11, and 3-20 for RT-27. The 
range of maximal fusion was >50% for C2C12 and RT-11, and <20% for RT-27.
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control gene-trapped RT-11 (not shown) and differentiating L6-S myoblasts (see Fig. 
19 A, B, C) and is consistent with a redistribution of cathepsin B toward the 
membrane o f myoblasts destined for myotube formation.
The analyses of cathepsin B activity and protein levels, cathepsin B localization, 
and myogenic phenotypes are consistent with prediction II, and support a more 
specific role for cathepsin B in myoblast differentiation. Moreover, this role appears 
to be linked to myoblast-myoblast fusion events.
3.4 Transcriptional Regulation of Cathepsin B during Myogenesis
There are many possible regulatory mechanisms that might account for the 
myoblast specific pattern of cathepsin B expression during myogenesis. These include 
transcriptional, post-transcriptional, and endogenous inhibitors (Introduction, Fig. 9) 
Both differentiating L6-S and C2C12 myoblasts demonstrate a parallel “down-up” 
pattern of cathepsin B protein and activity levels. There is also an induction in levels 
of cathepsin B mRNA between myoblast and myotube populations (Fig 20.). 
Therefore, I analysed the potential for transcriptional regulation of cathepsin B during 
myoblast differentiation by assessing the promoter activity of cathepsin B in 
transiently transfected L6-S myoblasts.
I have assessed the promoter activity of cathepsin B in L6-S cells by transient 
transfection and Luciferase reporter assays using plasmids containing the 5’ promoter 
1 region of cathepsin B placed upstream of a reporter gene that has readily measurable 
enzyme activity. The Firefly Luciferase reporter system was used because of its 
sensitivity, low-background, and rapidity. More importantly, 10 different 5’ cathepsin
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Figure 29
Immunocytochemical Localization of Cathepsin B within 
C2C12 and RT-27 Myoblasts
Both cell lines were seeded at 8 x 103 to 5 x 104 cells per well, of a 24 well tissue culture 
plate and grown in 10 % horse serum-supplemented medium. At the desired state of 
differentiation or confluency, cells were fixed and then stained for cathepsin B using 
Rabbit anti-human liver cathepsin B IgG as the primary antibody and Texas Red- 
conjugated affinity-purified donkey anti-rabbit IgG as a secondary antibody (Methods:
2.12). In presumptive C2C12 (A) and RT-27 (C) the cathepsin B staining (arrows) was 
punctate and concentrated in the perinuclear region. In postmitotic fusing C2C12 (B), and 
RT-27 (D), there was a redistribution of cathepsin B towards the plasma membrane.
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B promoter 1 constructs have already been constructed and inserted into plasmids 
containing the luciferase cassette (Berquin et al. 1996). These plasmids have been 
shown to have high transfection efficiency in mammalian cell lines, and most of the 5? 
promoter constructs have already been shown to efficiently induce luciferase activity 
in human Glioblastoma cell lines.
The ultimate goal of these promoter analyses was to identify transcriptional 
mechanisms responsible for cathepsin B expression. It has already been determined 
that the 5’ promoter 1 region of the human cathepsin B gene contains E-box elements 
just up-stream of the initiation site and upstream recognition sequences that may 
recognise various transcriptional activators and repressors (Berquin et al. 1996). 
Moreover, fused versus non-fused populations of L6 myoblasts demonstrate 
differences in the expression of various non-muscle and muscle specific transcription 
factors (see introduction). Therefore, since fused versus non-fused populations also 
show an induction in levels of cathepsin B mRNA (Fig. 20), I have started this 
analysis by examining the promoter activities of two 5’ promoter 1 constructs 
transfected into L6-S myoblasts and measured at two stages of L6-S differentiation; 
division and fusion.
3.4.A Cathepsin B Promoter Activity is Induced during Myoblast-Myotube
Differentiation. All cathepsin B 5’ promoter analyses were carried out 
using Promega Genelight 2 plasmid kit which comes with four plasmids. Of these, the 
pGL2-basic vector was used as a negative control. It contains the luciferase cassette 
with SV40 intron and polyadenylation sequences; it does not contain promoter or 
enhancer sites. The pGL2-basic vector was engineered to incorporate a multicloning
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
127
site that allowed the insertion of various restriction length fragments of a 2.2 kb 
cathepsin B promoter sequence from the plasmid pICB8 (Fig. 30). Two of these pGL2 
plasmid constructs, pSCB2 and pSCB5, were used for my initial promoter analysis. 
Using Lipofectin reagent, each plasmid was cotransfected in triplicate with the 
pCMVB plasmid, which expresses bacterial B-galactosidase. L6-S myoblast and 
myotube cell extracts were assayed for both luciferase and B-galactosidase activity 
using luminescent assays as described in Materials and Methods (section 2.14.B) and 
the results are presented in Figure 31. For each cell population, the transfection 
efficiencies of pSCB2 and pSCBS were high as evidenced by the high levels of B- 
Galactosidase activity. Among cell populations, both myoblasts and myotubes 
demonstrated an induction of luciferase activity for both plasmid constructs pSCB2 
and pSCB8 relative to pGL2-basic promoter activity. Significantly, myotubes 
demonstrated approximately 2 fold greater levels of luciferase activity as compared to 
myoblasts. This is consistent with an induction in mRNA levels during myoblast- 
myotube differentiation. Induction of luciferase by the pSCB5 construct was greater 
than induction by the pSCB2 construct.
3.4.B The Next Step. As a first approach to localising the minimal promoter 
element(s) upstream of exon 1 ,1 am in the process of transfecting L6S rat 
myoblasts with each of the 10 deletion variants represented in Figure 30.
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Restriction Endonuclease Map of pSCBl and Deletion Variants
Plasmid pSCBl contains the whole 2.2 kb Sacl/Kpnl fragment presented at the top, 
including exon 1 (shaded box) and 0.3 kb of intron 1. Plasmids pSCB2-10 are deleted 
as shown and pSCB-B represents the pGL-2 basic plasmid control without promoter. 
Plasmids pSCBl-10 and pSCB-B were purified according to Methods: 2.14.A. Ail 
plasmids were obtained from the laboratory of Dr. Bonnie Sloane (Wayne State 
University, Detroit, MI).





























Transient Expression Assay in Differentiating L6S Myoblasts
One day before transfection, L6S and L6D3 cells were seeded in triplicate in 10% HS 
supplemented medium at 4 x 104 cells per well of a 12 well plate. After 20 hours of 
growth, 50 ng of 1:1 pCMVLacZ and either pSCB5 or pSCB2 plasmids were 
cotransfected using Lipofectin reagent (Methods: 2.14). After 48 hours, cells were 
collected and cell lysates prepared for Luciferase and P-galactosidase assays. Luciferase 
assay was performed on myoblast (solid bars) and myotube (striped bars) cell 
populations using 10 ul of extract and 50 ul of luciferase substrate. For P-galactosidase 
assay, 5 ul of cell extract was mixed with 33 pi of Lumigal reaction buffer and 50 pi of 
Lumigal chemiluminescence accelerator. Both assays were done in triplicate and activity 
was measured using a MicroLumat LB96P Luminometer. Activity was measured as 
relative luciferase light units (RLU), normalized by p-galactosidase activity and 
expressed as a percent of the activity obtained with the pGL2-basic control plasmid 
vector. To correct for background P-galactosidase activity, mock transfected cell lysates 
(transfected with carrier DNA) were assayed and used to correct P-galactosidase RLU 
reading according to Methods, section 2.14C.
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Discussion
It has been estimated that up to 20,000 of the 30,000 genes expressed during 
myoblast differentiation are expressed in a differentiation-specific manner (Gogos et 
al. 1996). Some of these genes are muscle-specific, others are nonspecific. The results 
reported in this dissertation provide evidence that the cysteine protease, cathepsin B, is 
one of the nonspecific genes expressed in a regulated manner during myogenesis. 
Unlike muscle-specific enzymes such as creatine phosphokinase (CPK) which 
demonstrate low, basal levels of activity prior to myotube formation, levels of 
cathepsin B activity are high in dividing, presumptive myoblasts. As these cells align 
to form linear arrays in preparation for fusion, levels of cathepsin B activity drop 
dramatically, then increase in a fusion-related manner characteristic of muscle-specific 
enzymes such as CPK (Dufresne et al. 1976; Ebisui et al. 1995). While earlier 
comparative studies between myoblast and myotube populations have demonstrated 
greater levels of cathepsin B in myotubes (Bechet et al. 1991; Ebisui et al. 1994), the 
current study appears to be the first to demonstrate a “down-up” pattern over the entire 
differentiation process in vitro.
There is considerable indirect and direct evidence suggesting that this “down-up” 
pattern of cathepsin B activity plays a role in myogenesis. First, the pattern is observed 
in two unrelated myoblast cell lines, mouse C2C12 and rat L6, but is not observed in 
nonfusing L6 myoblast variants or in LM fibroblasts. Second, during differentiation 
of both C2C12 and L6 myoblasts, cathepsin B is redistributed from the perinuclear
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region of dividing cells toward the membrane of fusing cells; this redistribution is not 
observed in nonfusing L6 myoblast variants or in LM fibroblasts. Third, the punctate 
nature of cathepsin B staining throughout differentiation is consistent with vesicular- 
mediated redistribution (Poretz et al. 1980; Sloane et al. 1994). Fourth, exposure of 
control myoblasts to CA074Me, the penetrating form of the cathepsin B selective 
inhibitor, inhibits myotube formation in a dose-dependent way. Fifth, reduced levels of 
cathepsin B are associated with alterations in the activity of the muscle-specific 
biochemical marker, creatine phosphokinase, but not in the activities of two 
nonspecific enzymes, lactate dehydrogenase and myokinase. Sixth, reduced levels of 
cathepsin B are associated with dramatic reductions in the extent of myotube 
formation (i.e., percent fusion) and the size of each myotube (i.e., the number of nuclei 
within a myotube). These latter results support a causal link between the expression of 
cathepsin B, creatine phosphokinase and myotube formation. This link is supported 
by studies from other laboratories. For example, Ebisui et al. (1994) reported that the 
addition of cysteine protease inhibitors to murine myoblasts reduced fusion-related 
increases in creatine phosphokinase activity (Ebisui et al. 1994). In a more recent 
study, Gogos et al. (1996) reported that cathepsin B gene-trapped C2C12 myoblasts 
transfected with sense cathepsin B cDNA formed myotubes similar to those formed in 
control myoblasts, while C2C12 myoblasts transfected with antisense cathepsin B 
cDNA formed myotubes similar to those formed in cathepsin B gene-trapped 
myoblasts (Gogos et al. 1996).
Evidence presented in this dissertation suggests that during myogenesis cathepsin 
B activity may be required to modify myoblast cytoskeletal or plasma membrane
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proteins o f myoblasts preparing for fusion. This suggestion is supported by the 
redistributed of cathepsin B from its site of synthesis toward the membrane of fusing 
myoblasts and by studies demonstrating that cytoskeletal proteins can be degraded by 
cathepsin B in vitro (Matsuishi et. al., 1992). Demonstration of cathepsin B co­
localization with plasma membrane or cytoskeletal proteins during fusion would 
strengthen this suggestion. Moreover, the punctate nature of cathepsin B staining 
during growth and fusion suggests that cathepsin B is localized and redistributed 
within lysosomal vesicles. Demonstration of cathepsin B co-localization with 
lysosomal markers would strengthen this suggestion.
While our observations implicate cathepsin B in myotube formation, there is 
considerable evidence that cathepsin B functions in concert with other proteases to 
mediate the complex recognition and fusion events associated with the myoblast 
differentiation. For example, calpain II, like cathepsin B exhibits a peripheral 
distribution in fusion-competent myoblasts (Schollmeyer 1986) and a fusion-related 
increase (Kaur and Sanwal 1981). Moreover, exteriorization of m-calpain activity 
appears to be necessary for rat myoblast fusion (Brustis et al. 1994). It has also been 
reported that a matrix metalloprotease provides the insulin degrading enzyme activity 
required for the initiation of differentiation, and that the addition of selective, matrix 
metalloprotease inhibitors inhibits L6 rat myoblast differentiation (Kayalar and Wong 
1989). The evidence presented in this dissertation implicates the cysteine protease, 
cathepsin L, and the asparty! protease, cathepsin D. Despite the lack of specific 
substrates and selective inhibitors for these proteases, both demonstrate a pattern of 
activity similar to that for cathepsin B during myoblast differentiation. In the case of
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cathepsin L, this “down-up” pattern of activity is paralleled by a similar pattern of 
protein levels. Moreover, these patterns of expression are not observed in nonfusing 
variants of L6 myoblasts. The association between the differentiation-related patterns 
of cathepsin B activity and cathepsins L-type and D activities could reflect their 
interaction in vivo. For example, cathepsin D has been implicated in the processing of 
cathepsin B (Nishimura and Kato 1987), while cathepsin L and cathepsin B are closely 
related cysteine proteases. In fact, the relatedness of cathepsins L and B, and the 
pattern of their activities in cathepsin B-gene trapped C2C12 myoblasts suggest an 
intriguing possibility concerning their interaction during myogenesis. Reductions in 
levels of cathepsin B activity and protein in fusing populations of cathepsin B gene- 
trapped myoblasts appear to be complemented by increases in levels of cathepsin L- 
type activity and cathepsin L protein. Such a complementation would be predicted if 
cathepsin L expression were induced, for example by the modulation of transcription 
factors, to compensate for reduced levels of cathepsin B in fusing RT-27 myoblasts. If 
such a compensatory mechanism operates, knockout of either the cathepsin B gene or 
the cathepsin L gene in vivo may not affect skeletal muscle development. This may 
require knockout of both genes. While these possibilities remain to be examined in 
vivo, cathepsin L does not appear to compensate for cathepsin B during differentiation 
of cathepsin B gene-trapped myoblasts in vitro. CPK activity and myotube physiology 
are negatively affected despite the increased expression of cathepsin L. It is more 
likely that the alterations in the myogenic phenotype of cathepsin gene-trapped 
myoblasts are directly related to their reduced levels of cathepsin B.
Changes in levels of cathepsin B activity during myoblast-myotube differentiation
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can reflect several mechanisms including alterations in transcription, translation, post- 
translational processes, and/or interactions with endogenous inhibitors (Bechet et al. 
1991). Reports suggest that cysteine protease inhibitors affect levels of protease 
activity by binding to their target enzymes, with varying affinities, in a one-to-one 
stoichiometric fashion (Green et al. 1994). The high affinity of these inhibitors to 
cysteine proteases suggests that their major cellular role is to protect cells against 
uncontrolled protease activity during biological processes. It follows that the 
alterations in proteolytic activity during myoblast differentiation could reflect 
differences in the balance between proteases and their endogenous inhibitors. Our 
early studies, and those of others in the field, do not support this mechanism (Jane and 
Duffesne 1994; Kirschke et al. 1990; Ebisiu et al. 1995). There is also some evidence 
that differences in levels of cathepsin B during myogenesis reflect alterations in 
cathepsin B isozyme patterns (i.e., post-translational mechanisms) (Bechet et al. 1991) 
and changes in the distribution of presumptive lysosomes within the cell (Poretz et al. 
1980). However, the parallel patterns of cathepsin B activity and protein observed 
during differentiation of L6 and C2C12 myoblasts are more consistent with regulation 
at the level of transcription. The results of Northern blot analyses support this 
possibility.
Northern blot analysis demonstrate that cathepsin B mRNA levels are induced 
during differentiation of L6S myoblasts with signal intensity of the major 2.2 kb band 
increasing at the post-mitotic/early fusion stage of L6S differentiation. These results 
are also supported by the studies of Collela et al. (1986) reporting a 7-8 fold increase 
in a 23-2.5 cathepsin B mRNA between non-fused and fused populations of L6S
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myoblasts, and by the studies of Ebisui et al. (1995) reporting an 18% increase in a 2.3 
kb cathepsin B mRNA transcript observed in fused C2C12 myoblasts. In addition, 
Tailandier et al. (1996) reported that an increase in cathepsin B activity paralleled a 
111% increase in cathepsin B mRNA levels of atrophying rat soleus muscle. In post­
fusion L6S myotubes, the intensity of the 2.2 kb band decreases dramatically and is 
consistent with evidence that cathepsin B activity and intracellular staining intensity is 
greatly reduced in older L6 myotubes (Jane and Duffesne 1994) and in X-gal stained 
C2C12 myotubes (Gogos et al. 1996).
While the Northern blots suggest that cathepsin B mRNA is induced, a “down-up” 
pattern was not observed. This could reflect the time of RNA sample preparation. For 
example, the low band intensity on day 2 may reflect the end point of a transient 
decrease in mRNA from day 1 to day 2. The subsequent increased banding intensity 
on day 3 would then reflect an “up” part of cathepsin B mRNA expression similar to 
that observed for levels of cathepsin B protein and activity. A more detailed analysis 
of mRNA at 12 hour intervals after plating should help to resolve this question.
Non-fusing L6D3 myoblasts do not demonstrate the same induction pattern of 
cathepsin B mRNA as does L6S. Levels of the 2.2 kb mRNA transcript are high 
throughout growth consistent with high levels of cathepsin B activity and protein 
expression. Interestingly, a minor 4.0 kb band also appears during late exponential 
stages of L6D3 myoblast growth and is consistent with the expression of minor 4.0 
and 5.0 kb transcripts detected in murine tumors (Qian et al. 1991).
Ultimately, variation in the size of cathepsin B mRNA transcripts reflects 
alterations in the structure of the cathepsin B gene. Comparisons of the structure of
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murine and human cathepsin B genes demonstrate that the human gene spans 27 kbs 
and contains 13 exons (Fong et al. 1992; Sloane et al. 1994) whereas the murine gene 
spans 20 kbs and contains 10 exons (Ferrare et al. 1990; Qian et al. 1991). Although 
the size and junction points of all exons were found to match exactly between the two 
species, murine and human cathepsin B genes differ in the size and sequence of their 
introns and untranslated regions (UTRs). As a result, mRNA transcripts are highly 
heterogeneous especially in their 5’ and 35 UTRs. Northern blot analyses of mRNA 
transcripts across species demonstrates that the human cathepsin B gene of normal 
cells and tissues usually generates two major transcripts of approximately 2.3 and 4.0 
kb whereas only a 2.3 kb transcript is usually found in normal murine tissues (Qian et 
al. 1991). Bovine cells generate a major band of 2.6 kb and a minor band of 3.2 kb in a 
developmental and tissue specific manner. In general, differences in cathepsin B 
transcript size is mainly attributed to interspecies differences in the 3’ untranslated 
regions. For example, each of the human, bovine and murine cathepsin B genes 
contains three polyadenylation sites in different locations of their respective 3’-UTRs 
(Mordier et al. 1995). Therefore, alternate polyadenylation can generate short mRNA 
transcripts (e.g. 2.3 kb in human, bovine and murine) or long mRNA transcripts (e.g.
4.0 kb in human). In the mouse however, whether the long mRNA species of 4.0 and
5.0 kb only occur in tumors (Moin et al. 1989) or in normal tissues (Qian et al. 1991) 
is a matter of controversy. Interestingly, the demonstration of the long 4.0 kb species 
at exponential growth of non-fusing L6D3 may be characteristic of their tumor-like 
phenotypes such as rapid proliferation, foci formation and uncontrolled overexpression 
of intracellular and extracellular lysosomal protease activities.
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Alternative splicing can also contribute to the heterogeneity of cathepsin B 
mRNA expressed between species and among different cells and tissues within the 
same species. For example, the two human variant 3’-UTRs accounting for the short 
2.3 kb and the long 4.0 kb mRNA transcripts (bands on northern analyses) are formed 
by alternative splicing of exons 11 and 12 (Gong et al. 1993). In addition, Sloane et al. 
(1994) described a novel exon (2a/2b) in the 5’-UTR that can also be alternatively 
spliced or even skipped altogether. Gong et al. (1993) have identified splice variants in 
tumors and normal tissues that lack exon 2; these have been confirmed by Berquin et 
al (1996) using RT-PCR (reverse transcriptase-polymerase chain reaction) and 
5’RACE (rapid amplification of cDNA-ends). Together these studies suggest that the 
expression of cathepsin B may be regulated in part at the level of mRNA processing.
Another mechanism that can generate transcript heterogeneity is through the use 
of alternate promoter regions. In the mouse cathepsin B gene, exon 2 contains a 
translation initiation codon that corresponds to the translation initiation codon of the 
human exon 3 (Qian et al. 1993). In addition, intron 1 was found to contain 2 
additional exonic regions such that there are now three known 5’-UTRs referred to as 
leaders, LA, LB & LC (Rhaisse et al. 1993), indicating a potential for more promoter 
regions. In humans, the major transcripts detected thus far are initiated in exon 1. 
However, one human cathepsin B transcript was found to be initiated in exon 3 while 
another has been found to be initiated in exon 4 (Berquin and Sloane 1996). Therefore, 
there may be as many as 3 promoter regions from which both human and murine 
cathepsin B transcription can be initiated.
Whatever the molecular basis for alterations in cathepsin B activity during
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myoblast differentiation, the “down-up” pattern we observe is consistent with a 
process-specific transition from general housekeeping functions (e.g., protein turnover 
and cell metabolism) in dividing cells (Bohley and Seglen, 1992), to more specific 
functions (e.g., myotube formation) in committed myoblasts. This interpretation is not 
without precedence. Similar process-specific transitions in function are implicit in the 
more specific roles of other ubiquitous proteases, for example CANPs and 
metalloproteases, in myogenesis (Kaur and Sanwal 1981; Gourdin and Holland 1995; 
Hayashi et al. 1996; Dourdin et al. 1997), and in the more specific roles of cathepsin B 
in other processes, for example in the generation of thyroid hormones, in bone 
resorption, and in the presentation and processing of antigenic proteins (reviewed in 
Mort and Buttle 1997). Recent analyses of the transcription factor binding sites in the 
cathepsin B promoter are also consistent with a housekeeping to muscle-specific 
transition in function.
Qian and colleagues were the first to sequence the 5’ putative promoter region of 
the murine cathepsin B gene and demonstrated this region to be TATA-less containing 
a high percentage of G and C nucleotides as well as several Spl transcription factor 
binding sites (Qian et al 1991). The putative promoter region upstream of exon 1 of 
the human cathepsin B gene was also found to have characteristics of a housekeeping 
gene and suggested that the expression of the human and murine cathepsin B genes 
was constitutive, rather than specifically regulated (Gong et al. 1993). This supports 
the role of cathepsin B in general catabolic processes such as intracellular protein 
turnover (Bohley and Seglen 1992). However, Berquin’s analysis o f the putative 
promoter region of the human cathepsin B gene demonstrated that at one nucleotide
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from the presumed transcription start site, there is a 5 of 5 (5/5) base pair (bp) match 
to the consensus sequence for the MyoD family of bHLH regulators. Moreover this 
region also contains a 7/9 bp match with the binding site for the YY1 initiator, and a 
10/10 bp match with the binding site for the upstream stimulatory factor, USF. Each of 
these elements are known to recognize transcription factors that are reported to be 
directly involved in skeletal muscle-specific gene expression, as discussed in the 
Introduction of this dissertation. An extensive computer analysis of the human 
cathepsin B promoter has demonstrated other putative consensus sequences upstream 
of the presumed transcription start site, including multiple API, AP2, APS, and AP4 
sites, 5 CTF-NFI sites, 3 NFkB sites, and MEF-2 sites (Berquin and Sloane 1996). A 
simplified representation of some of these binding sequences is presented in Figure 32.
The murine cathepsin B promoter region upstream of exon 1 shares some of the 
sequences present in its human counterpart, for example it has several SP1, API and 
CTF/NF-1 sites, as well as an E-box element 10 bp upstream of the presumed 
transcription start site. Therefore, although there are considerable differences between 
the overall sequences of the human and murine cathepsin B promoters, there appear to 
be functional homologies in areas that are important to the specific regulation of the 
cathepsin B gene. Therefore, it would appear that the both the human and murine 
cathepsin B promoter regions contain structural elements that would permit a 
“housekeeping to muscle-specific” transition in function during myogenesis. 
Moreover, since both human and cathepsin B genes contain more than one promoter 
region with TATA and CAAT boxes, (Berquin and Sloane 1996; Rheas et al. 1993), 
each cathepsin B promoter region may be regulated independently in a tissue-specific
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F ig u re  32
Structure of the Cathepsin B Gene and its Putative 5’ Promoter 
Region Upstream of Exon 1
The cathepsin B gene is located on chromosome 8p22 and is comprised of 13 exons 
spanning more than 27 kilobases. The putative promoter region upstream of exon 1 
contains numerous potential binding sites including: E-box elements (5’-CANNTG), SP- 
1 sites (5’- GGGCGG), AP-2 binding sites (5’-CCCCAGGC), and CpG islands.
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manner. Such independent regulation could very well rely on the presence of various 
transcription factors whose relative concentrations are regulated during differentiation. 
The “down-up” pattern of cathepsin B expression during myoblast differentiation 
provides a hypothetical example for such a mechanism.
During myoblast differentiation, the high levels of cathepsin B expressed in 
dividing, presumptive myoblasts may reflect constitutive expression of enzymes 
involved in the general housekeeping catabolic functions. As these cells align and 
commit to differentiation, a decrease in factors that are involved in the constitutive 
expression of cathepsin B, for example SP1, would reduce their levels of cathepsin B 
and signal a transition in regulation of the cathepsin B gene. Increased levels of 
skeletal muscle-specific factors in postmitotic myoblasts could then induce cathepsin 
B expression directly by the binding of these factors to their putative binding elements 
in the promoter region of the cathepsin B gene, or indirectly by promoting the binding 
of other factors/co-factors. The high levels of MRFs during myoblast-myoblast fusion 
are consistent with these possibilities. Therefore, cathepsin B gene induction and the 
resulting housekeeping to differentiation specific transition in cathepsin B function 
may depend in part on the regulated expression of the MyoD family of bHLH and 
other related nuclear transcription factors. This, in turn, would be affected by cell- 
ECM and cell-cell interactions.
Finally, while the more specific function of cathepsin B may be regulated by 
transcriptional factors, one of it’s more specific functions may be to regulate the 
transcription of muscle-specific genes by the selective degradation of transcriptional 
activators and repressors critical for myoblast differentiation. Precedence for this kind
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of interaction has already been reported. For example, m-calpain, a differentiation 
regulated protease has been shown to act as a transcription factor regulator through 
proteolytic cleavage of the multifunctional transcription factor YYI, which is capable 
of repressing myogenic transcription (Walowitz et al. 1998).
While the regulatory mechanisms described above are hypothetical, transient 
transfection of L6S myoblasts with plasmids containing the putative 5’ promoter of the 
human cathepsin B gene placed upstream of the luciferase reporter gene did result in 
the induction of luciferase activity relative to control plasmid constructs. These 
results, albeit preliminary, demonstrate that there is cathepsin B promoter activity 
during myogenesis. While these studies are preliminary and offer indirect evidence for 
a myoblast specific regulation of cathepsin B promoter activity, gel mobility shift 
assays and site directed mutagenesis studies of putative promoter elements should 
provide more direct evidence.
The results described in this dissertation provide evidence that levels of cathepsin 
B activity and protein follow a “down-up” pattern of expression during myoblast 
differentiation. This pattern appears to be regulated at the level of transcription and is 
consistent with a housekeeping to muscle-specific transition in cathepsin B function. 
This function appears to be necessary for the formation of multinucleated myotubes. 
Ideas concerning the potential role and regulation of cathepsin B during myogenesis 
are summarized in Figure 33. According to this hypothetical scheme, dividing, 
presumptive myoblasts express housekeeping enzymes involved in energy utilization 
and cell metabolism, including high levels of cathepsin B activity. These cells are 
maintained as presumptive myoblasts by factors outside and within myoblasts such as
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high levels o f  the MyoD inhibitory factor Id. When presumptive myoblasts exit the 
cell cycle and commit to differentiate, they align, adhere and form linear arrays of 
prefusion, postmitotic myoblasts. The presumptive stage to postmitotic stage transition 
is accompanied by a decrease in levels of cathepsin B activity, signaling a transition in 
the regulation of cathepsin B expression. During this time cell-ECM and cell-cell 
interactions, through signal transduction mechanisms, affect the expression of 
regulatory factors that affect differentiation including the down-regulation of Id and 
other inhibitors of skeletal muscle genes, and the up-regulation of MyoD and other 
activators o f skeletal muscle genes. During this time, cathepsin B levels increase in a 
fusion-related manner regulated perhaps by the binding of muscle transcription factors 
to promoter regions of the cathepsin B gene, and cathepsin B is redistributed from the 
perinuclear region of the cell toward the membrane of myoblasts destined to form 
myotubes. Myoblast cells that do not or cannot commit to differentiate do not 
demonstrate a housekeeping to muscle-specific transition in cathepsin B regulation or 
function. Under these circumstances, high constitutive levels of cathepsin B are 
maintained for general catabolic functions and cathepsin B is not redistributed toward 
the membrane of myoblasts.
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